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a   Intercept in regression analysis and constant in residual error models of 
population pharmacokinetics 
AGNP  Arbeitsgemeinschaft für Neuropsychologie und Psychopharmakologie 
AIC   Akaike Information Criterion 
ALT  Alanine aminotransferase 
ANOVA  Analysis of variance 
APA  American Psychiatric Association 
AST Aspartate aminotransferase 
b   Regression coefficient in multiple linear regression analysis and constant 
in residual error models of population pharmacokinetics 
BMI   Body mass index 
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CGI   Clinical Global Impression  
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CYP   Cytochrome P450 enzyme system 
CYP1A2  Cytochrome P450 isoenzyme 1A2 
CYP2C9  Cytochrome P450 isoenzyme 2C9 
CYP2C19  Cytochrome P450 isoenzyme 2C19 
CYP2D6  Cytochrome P450 isoenzyme 2D6 
CYP3A4 Cytochrome P450 isoenzyme 3A4 
D   Dose 
d   Day 
df  Degree of freedom 
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Nervenheilkunde 
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F   Bioavailability; statistical test parameter in ANOVA 
FDA   Food and Drug Administration  
Abbreviations 
FOCE  First order conditional estimation method in WinNonMix™ 
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γ-GT  Gamma-glutamyl transferase 
hr  Hour 
HAMD  Hamilton Depression Rating Scale 
HPLC   High-performance liquid chromatography 
5-HT  Serotonin 
IBW   Ideal body weight 
ICD-10  International Classification of Diseases and Related Health Problems, 
10th edition 
IM   Intermediate metabolizer 
k01  Absorption rate constant 
k10  Elimination rate constant 
k12, k21  Distribution rate constants from the central to the peripheral 
compartment in a two-compartment model 
kg  Kilogram 
L  Litre 
LBW   Lean body weight 
mACh  Muscarinic cholinergic 
MAOI   Monoamine oxidase inhibitor 
mg  Milligram 
mL  Millilitre 
mm HG  Millimetres of mercury, measurement of blood pressure 
mmol  Millimol 
MPE   Mean prediction error 
MSE   Mean squared error 
NA  Noradrenaline 
n Number 
ng  Nanogram 
NSAID  Nonsteroidal antiinflammatory drugs 
NSSA   Noradrenergic and specific serotonergic antidepressant 
OFV   Objective function value 
OR   Odds Ratio 
p  Significance level in statistical tests (probability of a type I error) 
P   Probability 
PCR   Polymerase chain reaction 
PM  Poor metabolizer 
Abbreviations 
r2  Coefficient of determination in multiple linear and logistic regression 
analysis 
rS   Spearman’s correlation coefficient 
RFLP   Restriction fragment length polymorphism analysis 
RIMA   Reversible inhibitor of monoamine oxidase A 
Screa   Serum creatinine concentration 
SD   Standard deviation 
SE   Standard error 
SNRI  Selective noradrenaline reuptake inhibitor 
ss   Sum of least squares  
SSNRI  Selective serotonin and noradrenaline reuptake inhibitor 
SSRI   Selective serotonin reuptake inhibitor 
T  Statistical test parameter in a t-test 
TCA   Tri- or tetracyclic antidepressant 
t1/2  Half-life 
tmax   Time to reach plasma peak concentrations  
U  Unit 
UKU  UKU side effec rating scale 
UM  Ultrarapid metabolizer 
V1  Peripheral volume of distribution (two-compartment model) 
Vc  Central volume of distribution (two-compartment model) 
Vd  Volume of distribution (one-compartment model) 
Vd/F  Volume of distribution (one-compartment model) scaled by bioavailability 
WHO  World Health Organization 
α  Hybrid constant in two-compartment models 
β  Hybrid constant in two-compartment models 
ε   Residual error of population pharmacokinetic models 
η   Interindividual variability of population pharmacokinetic parameters 
Θp   Population mean of pharmacokinetic parameters 
Θi   Individual pharmacokinetic parameters in population pharmacokinetic 
analysis 
Θ1, Θ2 Shift parameter or multiplier associated with a specific covariate in a 
population pharmacokinetic model 
σ2   Variance 
χ2  Statistical test parameter in χ2 -testing
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1 Introduction 
1.1 Treatment of depression 
Depression occurs in 17% of the European population (Lecrubier 2001) and its global 
burden is expected to increase over the next decades. With respect to the extent of 
disability experienced by patients depression is estimated to become second among all 
diseases causing disability by the year 2020 (WHO 1996). In spite of this, the diagnosis 
of depression is often overlooked because it is masked by somatic symptoms and has 
the stigma of a mental disease. In Germany, recognition and treatment of depression 
still remains deficient: the diagnosis of depression is not recognised in over 30% of 
depressive patients and in about 50% treatment is inadequate (Sachverständigenrat für 
die Konzertierte Aktion im Gesundheitswesen 2001). These deficiencies are most 
obvious in primary care and elderly patients. Thus, the German Ministry of Education 
and Research initialised the “Kompetenznetz Depression” that promotes joint research 
between universities, state hospitals, psychiatrists and general practitioners to improve 
the treatment of depression. 
So far, the cause of depression is not well understood but genetic, social, cognitive, 
psychodynamic as well as biologic factors are discussed to trigger its occurence within 
a vulnerability-stress-model. The German guideline for the treatment of affective 
disorders (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde 
(DGPPN) 2001) includes both, neurobiological and social factors when recommending 
antidepressant drug treatment and psychotherapy alone or in combination as first 
choice to treat unipolar depression. For bipolar depressive disorder, lithium, 
carbamazepine, and valproic acid are administered as mood stabilisers and 
antidepressants serve as additional medication in case of initial treatment failure. 
Initially, antidepressive medication should be given over a time period of at least three 
weeks before adapting the dose, changing medication or combining several 
antidepressants (Figure 1). 
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Figure 1: Treatment of depression according to the German guideline (DGPPN 2001) 
Depression 
bipolar unipolar 
mild moderate severe 
St. John’s Worth 
Antidepressant according to sedating or activating effect and
side effect profile 
Basic psychotherapy 
Treatment evaluation after 3–6 weeks 
success 
Dose adjustment 
Change of antidepressant 
Combination with lithium or other 
antidepressants 
Lithium 
failure 
Maintenance therapy for 6–18 months 
Carbamazepine or 
valproic acid 
Combination with 
antidepressant 
failure success 
Electroconvulsive therapy 
Prophylaxis in case of > 2 depressive episodes in 5 years, bipolar disorder or elderly 
patients 
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The choice of a specific antidepressant depends on the individual patient’s clinical 
presentation, the predicted response and the antidepressant’s side effect profile. 
Tricyclic antidepressants (TCAs) represent the first generation of antidepressants and 
are characterized by good clinical efficacy but high risk for vegetative side effects and 
life-threatening intoxications, such as arrythmia, seizures or delusion. Irreversible 
monoamine oxidase inhibitors (MAOI) require a special diet because of the risk of a 
hypertensive crisis in combination with dietary tyramine. This led to the market 
introduction of drugs that are better tolerated and have a low risk of toxic effects such 
as selective serotonin reuptake inhibitors (SSRIs), reversible monoamine oxidase A 
inhibitors (RIMA), selective noradrenaline reuptake inhibitors (SNRI), or new 
antidepressants with dual principle of action such as mirtazapine (noradrenergic and 
specific serotonergic antidepressant, NSSA) or venlafaxine (selective serotonin and 
noradrenaline reuptake inhibitor, SSNRI). These substances are equally effective and 
easier to handle because their side effect profile does not require careful dose increase 
when starting antidepressant treatment. The structures of the antidepressants studied 
in this thesis are given in Figure 2. 
1.2 Mechanism of action of antidepressants and mood stabilizers 
Antidepressants enhance the serotonergic, noradrenergic and dopaminergic 
transmission in the brain. These effects are achieved by inhibition of serotonin or 
noradrenaline reuptake from the synpatic cleft into the neuron (TCAs, SSRIs, SNRIs, 
NSSRIs), by inhibition of the monoamine metabolism via the monoamine oxidase 
(tranylcypromine, moclobemide) or by blocking specific receptors, for example 
presynaptic noradrenaline-α2 receptors and serotonergic 5-HT2- and 5-HT3 receptors 
thus enhancing the stimulation of 5-HT1A autoreceptors (mirtazapine). With chronic 
administration of antidepressants the monoamine receptors adapt their responsiveness 
by down-regulation of noradrenaline-β receptors, noradrenaline-α2 receptors and 
serotonin-5-HT1A autoreceptors and by up-regulation of noradrenaline-α1 receptors and 
dopamine-D2 receptors (Ebert 2001). Altogether these effects lead to a modulation of  
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  Doxepin  Fluvoxamine 
 
  Imipramine   Mirtazapine 
 
  Nortriptyline   Paroxetine 
 
   Sertraline    Venlafaxine 
 
Figure 2. Structures of antidepressants evaluated in this thesis 
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second messenger systems and gene expression that causes the antidepressive effect 
with a delay of 3-6 weeks.  
The antidepressants’ side effect profiles are based on their activity on specific receptor 
sites and varies among the antidepressant  agents (Table 1).  For example, inhibition of 
 
Table 1. Receptor binding profiles of antidepressants* 
 
Antidepressant 
 
Class 
5-HT 
re-
uptake
NA  
re-
uptake
α1   
inhi-
bition
mACh 
inhi-
bition 
H1   
inhi-
bition 
5-HT2A 
inhi-
bition 
Amitriptyline TCA ++ ++ ++ ++ +++ ++ 
Citalopram SSRI +++ - n.a. n.a. n.a. n.a. 
Clomipramine TCA +++ ++ ++ ++ ++ ++ 
Desipramine TCA + +++ + + + (+) 
Doxepin TCA (+) ++ ++ ++ +++ ++ 
Fluoxetine SSRI ++ + - - - - 
Fluvoxamine SSRI +++ - - - - (+) 
Imipramine TCA ++ ++ + ++ ++ + 
Maprotiline TCA - +++ ++ (+) +++ + 
Mianserine TCA - + (+) (+) +++ +++ 
Mirtazapine NSSA - - (+) (+) ++ +++ 
Moclobemide RIMA - - - - - n.a. 
Nortriptyline TCA + +++ ++ + +++ ++ 
Paroxetine SSRI +++ (+) - + - - 
Reboxetine SNRI - +++ - - - - 
Sertraline SSRI +++ - (+) (+) - - 
Tranylcypromine MAOI + (+) - - - - 
Venlafaxine SSNRI ++ (+) - - - n.a. 
Viloxazine SNRI - ++ n.a. - n.a. n.a. 
* adapted according to Möller 2000b 
Inhibition constant Ki: +++ < 10; ++ 11-100; + 100-200; (+) 200-1000;(-) > 1000 nmol/L 
5-HT: serotonin; NA: noradrenaline; α1: noradrenergic; mACh: muscarinic cholinergic; H1: 
histaminergic; TCA: tri- or tetracyclic antidepressant; SSRI: selective serotonin reuptake 
inhibitor; NSSA: Noradrenergic and specific serotonergic antidepressant; RIMA: reversible 
inhibitor of monoamine oxidase A; SNRI: selective noradrenaline reuptake inhibitor; MAOI: 
monoamine oxidase inhibitor; SSNRI: selective serotonin and noradrenaline reuptake inhibitor; 
n.a.: data not available 
6                                                                                                                 Introduction 
histamine-H1 receptors leads to weight gain and drowsiness; anticholinergic effects 
cause constipation, blurred vision and dry mouth; antagonism of noradrenaline-α1 
receptors results in dizziness, decreased blood presure or drowsiness; serotonin-5-HT2 
receptor stimulation leads to agitation, akathisia, anxiety, panic attacs, insomnia and 
sexual dysfunction and agonism of serotonin-5-HT3 receptors causes nausea, 
gastrointestinal distress, diarrhea, and headache (Möller 2000a). 
Bipolar depressive disorder is characterized by both depressive and manic episodes 
and is treated with mood stabilisers such as lithium, carbamazepine or valproate as 
first choice. Antidepressants represent an additional treatment option for depressive 
episodes but are second in line due to their potential to induce mania. So far, the 
mechanisms underlying the mood-stabilising effect are not well understood but the 
mechanisms of action of the medications are. Lithium inhibits the inositol-
monophosphatase and influences other second-messenger systems such as the 
intracellular calcium concentration, adenylat cyclases, G-proteins or proteinkinase C. It 
activates the serotonergic transmission and modulates dopaminergic, noradrenergic, 
and cholinergic systems as well as the transmission of γ-aminobutyric acid (GABA). It 
modulates the circadian rhythm and gene expression of G-proteins, adenylate-cyclases 
or peptide hormones (Benkert and Hippius 2000). Valproate and carbamazepine 
directly reduce neuronal conduction by inhibiting sodium ion channels. They also 
modulate GABAergic and dopaminergic effects as well as other second messenger 
systems. 
1.3 Pharmacokinetics 
1.3.1 Definition of pharmacokinetic parameters 
Pharmacokinetics describe mathematically the fate of a drug in an organism over time. 
The organism is often characterized as a system of compartments into which a drug is 
absorbed, distributed and from which it is eliminated. Orally administered drugs 
penetrate from an absorption compartment such as the gastro-intestinal system into a 
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central compartment, for example the systemic blood circulation. Analysing the plasma 
concentration of a drug, the time (tmax) to reach plasma peak concentrations (cmax) is 
linked to the absorption rate that is determined by the absorption rate constant (k01) 
when the process follows first-order kinetics. The cmax depends on the bioavailability (F) 
of a drug, that describes the fraction of the administered dose reaching the systemic 
blood circulation. The drug is distributed in the body according to its physico-chemical 
properties and physiological factors, e.g. blood flow, concentration of plasma proteins, 
or proportion of extracellular fluid in the body. The extent of distribution is determined 
by the volume of distribution (Vd). The concentration of a drug may be higher in some 
physiological systems than in others, thus the body compartment may be divided in 
central and peripheral compartments, described by different volumes of distribution 
(e.g. Vc, V1) and distribution rate constants (e.g. k12, k21). The half-life (t1/2) is the time 
needed to reduce the plasma concentration of a drug by 50%. This parameter is linked 
to the elimination rate constant (k10), to the clearance (CL) and to the volume of 
distribution, as clearance determines the volume of the central compartment (Vc) that is 
cleared of a drug in a certain time. 
1.3.2 Pharmacokinetics of antidepressants and lithium 
The pharmacokinetics of antidepressants are often described by a two-compartment 
model. These substances have to be lipophilic in order to pass the blood-brain barrier 
and thus are likely to distribute into peripheral compartments. This lipophilic property 
may be one of the reasons why they undergo extensive metabolism in the liver and 
show a first-pass effect, leading to variable bioavailability ranging from 30 to 80% 
(Table 2). The time until peak plasma concentration is reached varies between 1 and 8 
hours. These drugs are mainly metabolized by the liver via oxidation by the cytochrome 
P450 enzyme system (CYP) and glucuronidation. In general, their half-life ranges from 
9-40 hours. Most antidepressants are highly bound to plasma proteins. The variation of 
protein binding may also affect clearance and volume of distribution. A linear 
relationship between dose and plasma concentrations exists for most antidepressants,  
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Table 2. Pharmacokinetic parameters of antidepressants* 
Antidepressant Bioavailability 
[%] 
Half-life  
[hr] 
Time to peak 
concentration 
[hr] 
Protein 
binding       
[%] 
Amitriptyline 33-64 15-47  1-5  94-97 
Citalopram 80 23-45  2-4  < 80 
Clomipramine 50 12-36  3-8  98 
Desipramine 50-68 15-25  2-6  73-92 
Doxepin 15-45 8-25  2-4  80 
Fluvoxamine > 53 9-28  2-8  70 
Imipramine 22-77 4-18  2  90 
Mirtazapine 48 20-40  2  85 
Nortriptyline 46-59 18-56  4-6  93-95 
Paroxetine > 64 8-44  1-11  95 
Sertraline > 44 22-36  4-8  99 
Venlafaxine 40-45 5  2-4  27-30 
* derived from the manufacturers’ product information 
 
except for paroxetine, fluvoxamine and clomipramine. The pharmacokinetic parameters 
of the drugs that were analysed in this work are detailed in Table 2 according to the 
manufacturers’ information. 
The pharmacokinetics of lithium differs significantly from that of the antidepressants 
because it is exclusively eliminated by the kidney. The elimination is linked to the 
excretion and reabsorption of sodium ions in the proximal tubules of the kidney. This 
variability results in an unpredictable half-life ranging from 18 to 36 hours in patients 
with normal renal function. Its bioavailability is 80-100% and depends on the type of the 
administered lithium salt. The time to reach peak plasma concentrations ranges from 1-
3 hours for lithium acetate and from 4 to 4.5 hours for lithium carbonate. 
1.4 Factors influencing pharmacokinetics 
1.4.1 Determination of factors influencing pharmacokinetics 
The pharmacokinetic behaviour of a drug is altered by factors affecting the absorption, 
distribution or elimination process. Food intake or the pH value of the gastro-intestinal 
system can affect drug absorption. The distribution can vary according to the 
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individual’s height, weight, sex, age or protein binding and elimination is altered by liver 
or renal function or the activity of metabolizing enzymes or transporters. Co-medication 
can influence every pharmacokinetic process for example by building complexes with 
the drug in the intestine, by replacing drugs at protein binding sites and by inhibiting or 
inducing metabolic enzymes or transporters. Nowadays, controlled clinical studies 
evaluate the influence of factors that are likely to be relevant in patients where the drug 
will be administered. The typical study design includes 10-20 subjects per study arm 
and 8-20 plasma concentration measurements per patient and dosing interval 
(Hildebrand 2003). These dense data allow the determination of the individual’s 
pharmacokinetic parameters from plasma concentration-time profiles. The parameters 
are then summarized for every study arm and compared for statistically significant 
differences. Covariates that are often evaluated during drug development are the effect 
of food, age, gender, renal or hepatic impairment or co-medication that is known to 
alter the plasma concentration of many other drugs. However, these studies consist of 
a small number of carefully selected participants and except for one particular factor all 
others influencing the pharmacokinetics are excluded. As the mechanisms underlying 
pharmacokinetic variability have been intensively studied over the last twenty years, 
this knowledge is now included in drug development. Nevertheless, old drugs still 
remain less well studied. 
Studies evaluating the influence of several covariates in a naturalistic clinical setting 
are rare because of the lack of dense pharmacokinetic data, but over the years new 
pharmacokinetic methods were developed that are based on a population approach 
rather than modeling individual pharmacokinetics. Nonlinear mixed-effects modeling 
can be used to describe and quantify the mean and variability of pharmacokinetic or 
pharmacodynamic parameters in a population. When analysing dense data, this 
method is applied to generate more accurate estimates of the variability within a 
population and to identify covariates explaining this variability (Food and Drug 
Administration 1999). However, it is also useful for pharmacokinetic or 
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pharmacodynamic analysis of sparse, unbalanced and heterogenous data (Sheiner et 
al. 1977). 
1.4.2 Factors influencing the pharmacokinetics of antidepressants and lithium  
The pharmacokinetics of antidepressants are altered by drug interaction, patients’ age, 
sex and weight, renal and hepatic function as well as smoking, alcohol and food. The 
ingestion of food increases the bioavailability of sertraline by 40% (Goodnick 1994). 
Chronic alcohol abuse induces metabolic liver enzymes and therefore increases 
clearance and first pass-effect. On the other hand alcohol may cause liver cirrhosis that 
results in impaired elimination. In the elderly or in females, plasma concentrations of 
antidepressants are often higher. The gender effect has been reported for amitriptyline, 
clomipramine, imipramine, nortriptyline, trazodone and mirtazapine (Frackiewicz et al. 
2000, Timmer et al. 2000). The influence of age has been found for most of the TCAs, 
SSRIs and mirtazapine (Preskorn 1993, Timmer et al. 2000, Bazire 2000). 
Oxidative drug metabolism is catalysed by the hepatic cytochrome P450 (CYP) 
enzyme system. Drug-drug interactions can be explained by inhibition or induction of 
these isoenzymes and mutations in the genetic code of some of these isoenzymes 
cause high variability in the elimination of antidepressants. Five enzymes (CYP3A4, 
CYP1A2, CYP2C9, CYP2C19, CYP2D6) account for the metabolism of the majority of 
commonly used drugs. CYP3A4 is the most frequent enzyme in the liver followed by 
CYP1A2, CYP2C9, CYP2C19 and CYP2D6.  
CYP3A4 catalyses the metabolism of many drugs such as carbamazepine, protease 
inhibitors, oral contraceptives and antipsychotics. This isoenzyme partly mediates the 
metabolism of all antidepressants to a varying degree as can be seen by reduced 
plasma concentrations when carbamazepine or barbiturates, potent inducers of 
CYP3A4, are co-administered (Goodnick 1994).  
Smoking and omeprazole induce CYP1A2 thus enhancing the metabolism of drugs that 
are substrates of this isoenzyme. This effect has been reported for most of the TCAs 
(Goodnick 1994). On the other hand, CYP1A2 is inhibited by fluvoxamine, 
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ciprofloxacine or nutritional flavonoides (Bazire 2000). Similarly to CYP3A4 the 
metabolism of antidepressants is mediated partly by CYP1A2. 
Other metabolic enzymes, for example the closely related CYP2C9 and CYP2C19 
isoenzymes, are involved to a variable extent in the metabolism of TCAs, citalopram, 
fluoxetine, sertraline and moclobemide. Drug interactions have been reported with 
fluvoxamine, an inhibitor of CYP2C9 and CYP2C19. This increases the plasma 
concentrations of amitriptyline, clomipramine, mirtazapine and warfarin (van Harten 
1993, Anttila et al. 2001). In addition, the CYP2C9 and CYP2C19 genes are polymorph 
and the genotype is linked to enzyme activity. 
Variations due to genetic polymorphism range from the complete loss of enzyme activity 
(poor metabolizer), decreased (intermediate metabolizer) to normal enzyme activity 
(extensive metabolizer). Poor metabolizers are homozygous or heterozygous carriers 
of two defective alleles, intermediate metabolizers possess one functional and one 
defective allele and extensive metabolizers are carriers of two functional wild type 
alleles. Twelve CYP2C9 alleles causing different enzyme activity are known, but only 
the defective alleles CYP2C9 *2 and CYP2C9 *3 are of clinical importance (Aynacioglu 
et al. 1999). 1-3% of Caucasians are poor metabolizers, whereas the genotype 
intermediate metabolizer occurs in up to 35% (Wormhoudt 1999, de Morais 1994). The 
potential impact of being a poor metabolizer can be seen when receiving standard 
doses of warfarine: poor metabolizers develop high warfarine plasma concentrations 
and are therefore at risk of bleeding complications (Aithal et al. 1999, Steward et al. 
1997, van der Weide et al. 2001). Another example is the clearance of phenytoin which 
is decreased in poor metabolizers (Kidd et al. 1999) and intermediate metabolizers 
(Ninomiya et al. 2000).  
Nine alleles have been identified resulting in reduced or defective enzyme activity of 
the CYP2C19 isoenzyme. Out of these only one defective allele (CYP2C19*2) occurs 
frequently in Caucasians. Pronounced ethnic differences exist with respect to the 
frequency of CYP2C19 deficiency: 12-23% Orientals but only 2-5% Caucasians are 
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poor metabolizers of CYP2C19. In contrast, intermediate metabolizers are seen more 
frequently in Caucasians (25%) (Xie et al. 1999). Reduced clearance in poor 
metabolizers of CYP2C19 has been shown with omeprazole (Leiri et al. 1996), 
lansoprazole (Furuta et al. 2001) and diazepam (Meyer 2000).  
Out of all cytochrome P450 isoenzymes CYP2D6 is the most active isoenzyme for the 
metabolism of antidepressants and thus most likely the cause of altered plasma 
concentrations due to drug interactions or genetic polymorphism of metabolising 
enzymes in antidepressive therapy. Antidepressant plasma concentrations rise when 
inhibitors of CYP2D6 such as cimetidine, paroxetine or fluoxetine are co-administered 
or when several substrates of CYP2D6, such as antidepressants, antipsychotics or β-
adrenoreceptor blockers are administered in combination (Goodnick 1994, Bazire 
2000).  
Genetic polymorphism of the CYP2D6 gene is associated with the extent of oxidative 
metabolism in the liver (Coutts and Urichuk 1999; Eichelbaum and Gross 1990). At 
least fifteen out of more than 50 mutations account for CYP2D6 deficiency but 
detection of CYP2D6 *3, *4, *5, *6 alleles and gene duplication is sufficient for a highly 
reliable prediction of the CYP2D6 phenotype (Griese et al. 1998; Sachse et al. 1997).  
Among Caucasians, 5-10% are poor metabolizers of CYP2D6 and deficient in their 
capacity to metabolize CYP2D6 substrates. An example for this is the metabolism of 
desipramine which is decreased in poor metabolizers resulting in high serum 
concentrations and adverse drug effects (Bluhm et al. 1993; Spina et al. 1997). 
Similarly, the metabolism of venlafaxine is also reduced in poor metabolizers (Lessard 
et al. 1999). Due to polymorphism of the CYP2D6 gene, the dose needed to cause an 
antidepressant effect of nortriptyline ranges from 10 to 500 mg/d (Bertilsson et al. 1985, 
Dahl et al. 1996). Intermediate metabolizers of CYP2D6 or carriers of the CYP2D6*9 
allele show reduced enzyme activity (Raimundo et al. 2000, Griese et al. 1998). 
Duplication of the CYP2D6 gene may cause high enzyme activity and occurs in 1-10% 
Caucasians that are called ultrarapid metabolizers. Duplication of other CYP 
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isoenzymes has not been observed so far. Nevertheless, investigation of the lack of 
therapeutic response after intake of CYP2D6 substrates showed that gene duplication 
predicts high clearance in only 20-25% but high clearance does not predict duplication 
of CYP2D6 (Bergmann et al. 2001, Johansson et al. 1993).  
Population pharmacokinetic studies exist for nortriptyline and doxepin. Nortriptyline 
clearance is altered by the CYP2D6 genotype (Kvist et al. 2001) or inhibitors of 
CYP2D6 (Jerling et al. 1994) and relevant covariates of doxepin pharmacokinetics are 
age and weight (Meyer-Barner et al. 2002). 
The clearance of lithium is not affected by variations of hepatic metabolizing enzymes but 
highly variable because of its linkage to renal function and to the balance between sodium 
excretion and reabsorption in the proximal tubules of the kidney. This balance is 
influenced by the patient’s state of hydratation, sodium intake fever, pregnancy, old age or 
diseases that cause changes in renal perfusion or excretion capacity. Renal excretion of 
lithium is also affected by co-medication with diuretics, antihypertensives, corticoides or 
nonsteroidal antiinflammatory drugs (Michell 2000, Benkert and Hippius 2000). 
There are three population pharmacokinetic studies evaluating covariates on lithium 
pharmacokinetics. One study detected creatinine clearance and lean body weight to alter 
the lithium clearance (Jermain et al. 1991); another study found that age, total body 
weight, height and serum creatinine are significant covariates (Taright et al. 1994). A third 
study states a relationship between the lithium clearance and total body weight, age and 
serum creatinine (Yukawa et al. 1992). 
1.5 Relevance of therapeutic drug monitoring of antidepressants and 
lithium 
Therapeutic drug monitoring means to optimise individual dosing schedules by measuring 
the plasma concentrations of a drug. It is applied to drugs that are characterized by high 
interindividual pharmacokinetic variability, a narrow therapeutic range and a known 
relationship between plasma concentration and clinical effect.  
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With respect to psychopharmacotherapy, mood stabilisers, some antidepressants and 
some antipsychotics fulfill these criteria. Therapeutic drug monitoring is the standard of 
care in the treatment of lithium and anticonvulsants and recommended for tricyclic 
antidepressants, haloperidol and clozapine (Michell 2000) since blood concentrations 
of these drugs are highly variable. Thus, standard doses may cause subtherapeutic or 
toxic blood concentrations. 
Therapeutic drug monitoring of lithium is mandatory to avoid toxicity and to detect 
nonresponders and noncompliance. For these reasons it is recommended weekly in 
the first month of treatment, than monthly for five months and afterwards every three 
months (Benkert and Hippius 2000). Therapeutic serum concentrations range from 0.4 
to 1.2 mmol/L, whereas lower serum concentrations are desired for treatment 
augmentation; 0.6-1.2 mmol/L are recommended in the treatment of bipolar affective 
disorder or mania. Toxicity occurs at serum concentrations greater than 1.5-2.0 mmol/L 
and is characterized by coarse tremor, apathy, hyperreflexia, hypertonia, nausea, 
diarrhea, myoclonus, seizures, acute renal failure, cardiac dysrythmia and coma. 
Serum concentrations greater than 3.5 mmol/L are potentially lethal and necessitate 
hemodialysis (Michell 2000). Different methods exist for dose individualisation of 
lithium. Linear regression equations are used for estimation of initial lithium doses 
(Jermain et al. 1991, Pepin et al. 1980, Yukawa et al. 1993, Zetin et al. 1983). Doses 
can be individualised by nomographs and by serum concentration measurement after 
administration of a test dose (Gaillot et al. 1979, Cooper and Simpson 1982, Perry et 
al. 1986). Most of these methods take into account the creatinine clearance as well as 
weight and age and are only applicable to predefined dosing schemes. Thus, the 
physician needs to know all factors influencing the pharmacokinetics of lithium in order 
to plan dose individualisation before treatment initialisation.  
Computer-assisted methods that apply the theorem of Bayes allow the use of every 
dosing scheme and serum concentration measurement that may occur in clinical 
routine.   This  method  estimates   individual  pharmacokinetic  parameters   based  on  
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Table 3. Therapeutic ranges of tricyclic antidepressants 
 
 
Minimum 
effective 
concentra-
tion 
[ng/mL] 
Minimum 
toxic 
concentra-
tion 
[ng/mL] 
Conentration –
response 
relationship 
References 
Amitriptyline* 100 220 Bisigmoidal Hiemke et al. 2000 
Ulrich and Läuter 2002
Clomipramine* 175 450 Curvilinear Hiemke et al. 2000 
DUAG 1999 
Desipramine 100 150 Curvilinear Hiemke et al. 2000 
APA Task Force 1985 
Doxepin*  20 150 Not known Hiemke et al. 2000 
Leucht et al. 2001 
Imipramine* 175 350 Linear Hiemke et al. 2000 
APA Task Force 1985 
Nortriptyline  70 170 Curvilinear Hiemke et al. 2000 
APA Task Force 1985 
* sum of drug and active demethylated metabolite 
 
population pharmacokinetic parameters and their variability in combination with 
individual serum concentrations (Jaehde 2003).  
Therapeutic drug monitoring of tricyclic antidepressants is established to avoid 
subtherapeutic or toxic plasma concentrations and to check treatment compliance 
(American Psychiatric Association Task Force 1985). Therapeutic ranges are defined 
by a lower threshold for minimum effective plasma concentrations and an upper 
theshold for maximum effective or minimum toxic plasma concentrations. High plasma 
concentrations of TCA may be less effective in case of a curvilinear or bisigmoidal 
concentration- resonse relationship, and have the risk of cardiac and brain toxicity 
resulting in arrythmia, seizures or delirium (Table 3). 
An American cost-benefit calculation states that the costs associated with TCA brain 
toxicity overweight the costs of a single plasma concentration measurement at the start of 
antidepressive therapy. Assuming that sixty out of thousand depressed patients develop 
delirium because of high TCA plasma concentrations, the savings of therapeutic drug 
monitoring are estimated at about 350 $ per patient (Preskorn 1989). Although 
antidepressant doses given in the United States tend to be higher than in Germany, a 
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recent German study stresses the importance of therapeutic drug monitoring of TCAs. In 
this study including 108 patients, therapeutic plasma concentrations were associated with 
improved clinical response. Patients without therapeutic drug monitoring were more likely 
to develop plasma concentrations outside the therapeutic range and experienced more 
side effects. These beneficial outcomes were noted even in spite of a poor compliance of 
physicians to follow the recommendations of the therapeutic drug monitoring service 
during this study (Müller et al. 2003).  
In contrast to TCAs, the benefit of therapeutic drug monitoring of second generation 
antidepressants is controversely discussed. Different levels of evidence exist about the 
relevance of therapeutic drug monitoring: therapeutic drug monitoring appears to be 
useful in clinical routine for some of the newer antidepressants, but for most of the new 
antidepressants the clinical benefit remains unclear and therapeutic drug monitoring 
should therefore be reserved to particular clinical situations until more information is 
available. In general, the toxicity of antidepressants such as maprotiline and trimipramine 
is comparable to TCAs and thus therapeutic drug monitoring may be useful. New drugs 
are better tolerated, therapeutic ranges are mostly not well established and therapeutic 
drug monitoring should only be considered in cases of nonresponse, severe side effects 
or to check compliance (Table 4). 
The present thesis evaluates the benefit of therapeutic drug monitoring for venlafaxine, 
mirtazapine and the SSRI citalopram, fluvoxamine, paroxetine and sertraline. 
So far, venlafaxine is the only new antidepressant for which an association between 
plasma concentration, CYP2D6 genotype and clinical effect was demonstrated. Plasma 
concentrations were correlated to the decrease in the Montgomery and Åsberg 
Depression Rating Scale after 3 to 6 weeks of treatment and were significantly higher 
in responders than in nonresponders (Charlier et al. 2002). Additionally, poor 
metabolizers of CYP2D6 had higher plasma concentrations of the sum of venlafaxine 
and O-desmethylvenlafaxine and the ratio of the drug to its main metabolite was 
greater than one (Veefkind et al. 2000, Lessard et al. 1999).  
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Table 4. Proposed plasma concentration ranges of new antidepressants 
Antidepressant Daily dose 
[mg] 
Proposed 
concentration 
range*    
[ng/mL] 
Routine TDM 
useful  
Additional 
references 
Citalopram 20-60 50-130 Unclear Bjerkenstedt 
et al. 1985 
Fluoxetine** 20-80 100-400 Unclear Amsterdam et 
al. 1997 
Fluvoxamine 50-300 20-300 Unclear Härtter et al. 
1998 
Maprotiline 25-225 125-200 Yes Kasper et al. 
1993 
Mianserine 30-90 15-70 Unclear  
Mirtazapine 15-60 10-80 Unclear Timmer et al. 
2000 
Moclobemide 150-600 300-1000 Unclear Gex-Fabry et 
al. 1995 
Paroxetine 20-60 40-120 Unclear Rao et al. 
1999 
Reboxetine 2-12 10-100 Unclear  
Sertraline 50-200 20-50 Unclear Lundmark et 
al. 2000 
Trimipramine 25-150 150-350 Yes Isacsson et al. 
1997 
Venlafaxine** 75-375 200-400 Yes Charlier et al. 
2002, 
Veefkind et al. 
2000 
* according to Hiemke et al. 2000 
** Sum of drug and active demethylated metabolite 
 
Studies evaluating a concentration-response relationship are lacking for mirtazapine. 
There is a linear relationship between dose and plasma concentration over a dosing 
range of 15 – 80 mg/day (Timmer et al. 1995). Effective doses range from 5 to 60 
mg/day and result in plasma concentrations of 5 to 100 ng/mL (Timmer et al. 2000). Its 
sedative effect was found to be more prominent in low-dose treatment of mirtazapine 
(< 15 mg/day) (Kasper et al. 1997).  
SSRIs are characterized by a flat dose-response relationship as different doses in 
clinical trials are found to be equally effective. Thus, recommended therapeutic plasma 
concentrations are often estimated from the minimum dose in clinical trials (Preskorn 
1997). Studies evaluating concentration-response relationships of SSRIs were mainly 
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carried out in small patient groups and the results remain conflicting: most studies 
failed to show a correlation between plasma concentrations and the severity of 
depression but comparison between nonresponders and responders in some studies 
indicate minimum effective concentrations (Rasmussen and Brøsen 2000, Härtter et al. 
1998, Rao et al. 1999). However, a Scandinavian study in elderly depressed patients 
found that therapeutic drug monitoring helps to avoid unnecessary dose increases and 
thus drug costs were reduced by 10.2% (Lundmark et al. 2000).  
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2 Aims of the thesis 
The pharmacokinetics of antidepressants and lithium is highly variable among patients, 
thus considerable effort is made to contol this variablilty, e.g. by therapeutic drug 
monitoring, phenotyping or genotyping. Nevertheless, the benefit of plasma 
concentration control still remains unclear, especially with respect to new 
antidepressants.  
This thesis aims to provide basic information and tools to improve treatment with 
psychoactive drugs by therapeutic drug monitoring in a routine clinical setting.  
Three aspects were evaluated in detail from routine drug monitoring data and from a 
naturalistic clinical study in psychiatry: 
 
• The impact of CYP2C9, CYP2C19 and CYP2D6 genotypes on antidepressants’ 
plasma concentrations, side effects and treatment response.  
• The concentration-effect relationship for mirtazapine and factors influencing its 
pharmacokinetics applying population pharmacokinetic methods. 
• The use of population pharmacokinetic data to establish a computer-assisted 
service for dose individualisation of lithium.  
 
The applied statistical and pharmacokinetic methods were able to control multiple 
influencing factors occurring in clinical routine and focussed on linear and logistic 
regression as well as population pharmacokinetic analysis. 
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3 Patients and methods 
3.1 Study design 
3.1.1 Kompetenznetz Depression: Therapeutic drug monitoring and genotyping 
In 1998 a network was initiated in Germany to promote interdisciplinary research to 
better understand the etiology of depression and to improve antidepressive treatment. 
This network, the “Kompetenznetz Depression”, is sponsored by the German Ministry 
of Education and Research and includes six main multicentre projects that are further 
divided into subprojects. The subproject 3.8 was designed to answer questions about 
the potential of therapeutic drug monitoring of antidepressants to reduce side effects, 
the length of the patients’ stay in the hospital, and treatment costs. Four centres were 
involved: the Departments of Psychiatry of the Universities of Bonn and Mainz and the 
State Hospitals of Gabersee and Kiedrich. Patients were recruited from 2000 to 2003. 
Inclusion criteria were: (1) ICD-10 diagnosis F 3 (WHO 1992); (2) at least moderately ill 
according to the Clinical Global Impression Item Severity of illness (CGI > 4) (National 
Institute of Mental Health 1976, see Appendix 4); (3) start of an antidepressive 
monotherapy with amitriptyline, citalopram, clomipramine, desipramine, doxepin, 
fluvoxamine, imipramine, mirtazapine, nortriptyline, paroxetine, sertraline or 
venlafaxine. No restriction was made with respect to other drugs and a change of 
antidepressant therapy during the study. Exclusion criteria were: (1) Substance 
dependency or drug abuse within the last 3 months; (2) prior treatment with fluoxetine; 
(3) acute suicidal tendency; (4) pregnancy, (5) admission to the hospital by legal 
commitment or for crisis intervention. Patients gave their written informed consent for 
weekly antidepressant plasma concentration measurements and a clinical interview to 
assess treatment response and side effects during their stay in the hospital. This 
informed consent covered a maximum of ten weeks. Additional questionnaires 
assessed the direct treatment costs and the patient’s quality of life at the beginning of 
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the study, at discharge from hospital, and at three and six months post inclusion into 
the study.  
The subproject 3.8 co-operated with the project 5 of the Kompetenznetz Depression, 
that evaluated the molecular genetics of depression. Therefore, patients were also 
asked for their informed consent for a genetic analysis of factors underlying the 
response to the treatment of depression; therefore an additional blood sample was 
drawn. The studies were approved by the local Ethics Committees and were conducted 
according to the declaration of Helsinki. The data of patients who agreed to genotyping 
were analysed for the impact of CYP2C9, CYP2C19 and CYP2D6 genotypes on 
treatment outcome. 
An amendment was approved by the Ethics Committee of the Medical Faculty of the 
University of Bonn to include also patients treated with mirtazapine. These data were 
evaluated for a therapeutic range and factors influencing the pharmacokinetics of 
mirtazapine.  
3.1.1.1 Evaluation of the impact of CYP2C9, CYP2C19 and CYP2D6 genotypes on 
treatment outcome 
Subgroups were selected from the entire patient group that gave informed consent for 
genotyping. Patients were selected according to defined criteria to evaluate the 
relationship between genotype, trough plasma concentrations, response, and side 
effects. 
To evaluate the relationship between genotype and trough plasma concentration we 
calculated the mean dose-corrected plasma concentration of each antidepressant that 
was administered within the course of the study. For each antidepressant the median 
dose-corrected plasma concentration should represent the plasma oncentration of a 
typical extensive metabolizer and was calculated of all samples that were available for 
one drug; then patients’ mean dose-corrected plasma concentration was estimated as 
relative deviation with respect to the drug-specific median. Co-medication was stratified 
for substrates as well as inhibitors or inducers of CYP1A2, CYP2C9, CYP2C19, 
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CYP2D6 and CYP3A4. Mean coffee, cigarette and alcohol consumption was recorded 
on a 3-item scale with 0 = no consumption, 1 = up to 5 cups of coffee, 10 cigarettes or 
one glass of alcohol corresponding to 200 mL wine per day and 2 = consumption 
exeeding 1. Observations were excluded if plasma concentrations or doses were 
missing or steady-state was not reached. When more than one antidepressant was 
administered within the course of the study, only the antidepressant with the most 
observations was carried forward for analysis.  
Patients were selected for evaluation of a genotype-response relationship according to 
the following criteria: (1) at least three weekly observations carried out on the same 
antidepressant and (2) no change of diagnosis within the course of the study. The 
severity of depression was assessed by the Hamilton Depression Rating Scale 
(HAMD) and the Clinical Global Impression (CGI) (see 3.2.1, 3.2.2 and Appendix 1). 
Treatment response was defined according to the HAMD as 40% reduction in the total 
score from the first to the last observation. We chose 40% since, as a rule, the first 
observation was carried out after one week of drug treatment, thus excluding 
spontaneous remission. Response according to CGI was defined as a CGI 1 reduction 
of at least two points between the first and the last observation when CGI 2 was rated 
less than 4 at the last observation. Co-medication was stratified for benzodiazepines, 
antipsychotics, mood stabilisers, hypnotics and other antidepressants to control for 
putative interferences. 
The evaluation of the relationship between genotype and side effects was carried out 
on the side effects reported at the patients’ first observation after the start of 
antidepressive treatment. Side effects were assessed by the UKU side effect rating 
scale (see 3.2.3 and Appendix 2). Patients were divided into two groups according to 
the relevance of side effects at their first observation. Each UKU symptom item 
assesses the severity of side effects (not present, present to a mild, moderate, or 
severe degree) and the relationship to the drug (improbable, possible, probable). Side 
effects were judged relevant when at least four symptom items were rated moderate or 
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severe and possibly caused by the drug or when at least two symptom items were 
rated moderate or severe and probably caused by the drug. To control for putative 
interferences, co-medication was stratified for causing sedation or agitation, disturbing 
the gastro-intestinal system, influencing blood pressure, or provoking serotonergic or 
anticholinergic effects. 
3.1.1.2 Therapeutic range and population pharmacokinetic analysis of mirtazapine 
Patients treated with mirtazapine were carried forward for two evaluations: the analysis 
of a relationship between trough plasma concentration, response and side effects and 
the evaluation of factors influencing mirtazapine pharmacokinetics applying population 
pharmacokinetic methods. 
The evaluation of the the relationship between mirtazapine trough plasma 
concentrations and side effects was carried out on the entire mirtazapine data. The 
main side effects of mirtazapine are sedation and weight gain. Thus, the UKU items 
“sleepiness/sedation”, “increased duration of sleep”, “weight gain” and “global 
assessment of the patient’s performance” were evaluated separately to assess the 
relationship between trough plasma concentrations and side effects. Logistic 
regression controlled for the putative influence of co-medication with benzodiazepines, 
hypnotics or other sedative medication. In addition, observations that took place in the 
first week of mirtazapine treatment when side effects are generally more pronounced 
were analysed separately.  
To evaluate the relationship between mirtazapine trough plasma concentrations on 
treatment response, patients were selected according to the following criteria: (1) at 
least fourteen days of therapy with mirtazapine; (2) no co-medication with lithium, 
carbamazepine or other antidepressants; (3) no co-diagnosis of personality disorder. 
When treatment with mirtazapine was started 6-7 days before the first observation, 
pivotal efficacy trials showed a mean reduction of the HAMD score of about 25% 
(Bremner 1995). Therefore, we defined the response to mirtazapine as a reduction in 
the HAMD score of 40% or more from the first to the last observation.  
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The evaluation of factors influencing the pharmacokinetics of mirtazapine was 
performed by population pharmacokinetic analysis. A number of factors with possible 
impact on the pharmacokinetics of mirtazapine were recorded weekly: Co-medication, 
weight, height, age, gender, weekly AST-, ALT-, and γ-GT activity, serum creatinine 
concentration, smoking habits, coffee and alcohol consumption, blood pressure and 
pulse. We noted the time of ingestion of the last dose and of blood withdrawal reported 
by the patients. Co-medication was categorized into substrates, inhibitors or inducers 
of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4. Plasma concentrations were 
excluded from analysis when dosing schedules were missing, and when 
noncompliance or interference in the analytical assay was documented. For population 
pharmacokinetic analysis of mirtazapine, only observations with constant co-
medication were selected from every patient. 
3.1.2 A computer-assisted method for lithium dose individualisation 
The computer-assisted dose individualisation was established by specifying the 
population characteristics of lithium according to the current literature in tha Abbottbase 
pharmacokinetic software® for Bayesian curve fitting. This specification included 
population pharmacokinetic parameters and their variability as well as covariates with 
influence on lithium pharmacokinetics. 
The performance of the software that was extended by the lithium specification was 
validated with serum concentrations from routinely monitored inpatients that were 
retrospectively evaluated. Patient’s age, height, weight, serum creatinine, co-
medication and dosing schedule were noted from the patients’ charts. 
Each patient’s data were fitted by the extended software. Covariates were included if 
they reduced the residual sum of squares of the fit. To evaluate the predictive 
performance of the software, the accuracy and precision to predict the last observation 
of every patient was compared with three a-priori methods for dose individualisation 
(Pepin et al. 1980; Jermain et al. 1991; Yukawa et al. 1993). 
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3.2 Ratings 
3.2.1 Hamilton Depression Rating Scale 
The Hamilton Depression Rating Scale (HAMD) is the most common rating scale to 
measure the severity of depression. In this study the 17-item version was applied 
(Hamilton 1960, Appendix 1). The 17 items consist ot three or four grades scoring from 
0 to 2 or 3, respectively, with increasing severity of depressive symptoms. The single 
item scores are then summarized to the total score reflecting the severity of 
depression. 
The rater refers to the patient’s state of the preceding week taking into account the 
information she or he gets from the clinical interview as well as information from the 
hospital staff or from other persons who are in contact with the patient. 
The interrater reliability was found to range from 0.73 to 0.91. The validity was proven 
by its wide use in clinical studies (Collegium Internationale Psychiatriae Scalarum 
1981). Within the subproject 3.8, annual rater-trainings were performed. The intraclass 
correlation ranged from 0.71 to 0.83 calculated from the rating of three recorded clinical 
interviews. 
3.2.2 Clinical Global Impression 
The Clinical Global Impression (CGI) consists of three items that are evaluated 
separately: Severity of illness (CGI1), Global improvement (CGI2) and the Efficacy 
index (CGI3). The CGI can be applied to assess the treatment of every illness 
(Appendix 3 and 4). The rating is based on the rater’s experience with the specific 
disease. Similar to the HAMD, the CGI refers to the patients’ state of the preceding 
week.  
The inter-rater reliability was found to depend on the rater’s education (medical or 
nursing staff) and ranged from 0.35 to 0.66, the re-test reliability over 8 weeks ranged 
from 0.15 to 0.81 (Collegium Internationale Psychiatriae Scalarum 1981). Rater 
trainings among the study centres involved in this study revealed intraclass correlation 
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coefficients for the CGI1 of 0.85 and 0.86. The CGI is a quick and simple scale to 
measure treatment efficacy, and is widely used in psychiatric research although its 
validity is controversial (Beneke and Rasmus 1992). 
3.2.3 UKU side effect rating scale 
The UKU side effect rating scale was developed by Lingjaerde and colleagues from 
1981 to 1986 to assess the side effects of psychotropic drugs including 
antidepressants, antipsychotics and mood stabilisers (Lingjaerde et al. 1987). The 
scale contains 48 items assessing the severity of specific symptoms and their 
relationship to the analysed drug, a global assessment of the patient’s daily 
performance, and a statement of the consequences that side effects have on 
continuing medication. In the present study antidepressant side effects were assessed 
by an abridged version containing 30 symptom items, the global assessment and the 
statement of consequences (Appendix 2). Only those symptoms were assessed that 
occured during two days prior to the interview. 
The items can be either evaluated separately, in clusters of psychic, neurological, 
autonomic and other side effects, or in total. The inter-rater reliability was reported to 
range from 0.37 to 0.96 (Lingjaerde et al. 1987). 
3.3 Blood sampling 
Weekly venous puncture for antidepressant plasma concentration measurement was 
performed in the morning of the clinical interview. Blood samples were collected into 10 
mL tubes containing 0.2 mg EDTA as anticoagulant before administration of the 
antidepressants’ morning dose. In Bonn and Mainz, samples were transferred to the 
laboratories within three hours, centrifuged at 13000 x g for 10 min at 4°C or at 10000 
X g for 5 min, respectively, and stored at –20°C until analysis. Blood samples of 
Gabersee were sent to Mainz for analysis. All plasma concentration measurements 
were performed within three days. 
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Venous puncture for routine monitoring of lithium serum concentrations was performed 
in the morning before administration of the morning dose. Blood samples were 
collected in 10 mL tubes, transferred to the laboratory within three hours, clotted for 30 
min and then centrifuged at 2000 x g for 10 minutes at 4°C to obtain patients’ serum. 
The supernatant was stored at –20°C until analysis. 
3.4 Analytical methods 
3.4.1 Antidepressants 
The determination of antidepressant plasma concentrations was carried out in 
the laboratories of Bonn and Mainz by reversed-phase high-performance-liquid-
chromatography (HPLC) with ultra-violet detection. The method used in Bonn was 
described in detail by Frahnert et al. (2003). It includes solid phase extraction on 3 ml 
3M-Empore high performance extraction disk cartridges (Varian, Darmstadt, Germany) 
with the help of a Baker spe-12G vacuum instrument and was carried out according to 
the manufacturer’s instructions: the mixed-phase sorbent was conditioned with one ml 
methanol followed by one ml water; then 0.9 ml supernatant, 0.1 ml melperone (3000 
ng/ml) as internal standard and 2.0 ml 0.1 M potassium dihydrogenphosphate buffer 
(pH 6.0) were mixed in 16 x 100 mm polypropylene tubes (Sarstedt, Nymbrecht, 
Germany). The sample was transfered and passed through the extraction disk 
cartridge. To eliminate interferences, the cartridge was washed with one ml water, one 
ml 1 M acetic acid, one ml n-hexane, two ml n-hexane:ethyl acetate (1:1) and one ml 
methanol. The antidepressants and atypical antipsychotics were eluted with one ml    
2-propanol : ammonia solution (25%) : dichloromethane (20:2:78). The eluent was 
evaporated to dryness, the residue dissolved in 250 µl acetonitril:water (3:7) and 100 µl 
was injected in a HPLC system consisting of a Bischoff 2200 high-performance liquid 
chromatography pump (Bischoff, Leonberg, Germany), a solvent degasser unit SDU 
2003 (Bischoff, Leonberg, Germany) and a Waters Intelligent Sample Processor (WISP 
717) equipped with a cooling module at 4°C (Millipore-Waters, Eschborn, Germany).  
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Table 5. Assay specification for measuring antidepressants in Bonn* 
Antidepressant Validation 
range     
[ng/mL] 
Plasma 
concen-
tration 
[ng/mL] 
Relative 
error     
[%]        
(n = 10) 
Intra-assay 
coefficient 
of variation 
[%]         
(n = 10) 
Inter-assay 
coefficient 
of variation  
[%]         
(n > 10) 
Amitriptyline 10-500 75 1.9 1.7 1.9 
  100 2.6 2.6 7.2 
  200 3.4 2.6 6.3 
Citalopram 5-300 10 18.7 5.9 8.7 
  50 -2.2 1.5 1.3 
  100 0.4 1.3 2.6 
Clomipramine 10-750 75 -2.8 3.1 2.9 
  100 -0.4 5.2 7.6 
  300 -0.8 4.6 5.9 
Norclomipramine 10-750 75 -1.2 3.2 3.7 
  100 2.1 5.7 5.8 
  300 -0.3 1.5 3.7 
Desipramine 10-500 75 0.1 4.2 2.5 
  100 -2.9 4.6 8.7 
  200 -0.4 2.1 6.5 
Doxepin 5-500 75 0.8 2.2 1.9 
  100 2.0 2.7 8.3 
  200 -1.3 3.0 7.3 
Nordoxepin 5-500 75 0.5 3.0 2.5 
  100 7.0 2.8 7.2 
  200 0.9 2.3 7.2 
Fluvoxamine 5-500 10 1.7 8.7 5.8 
  50 7.2 4.9 4.8 
  150 6.8 3.6 3.3 
Imipramine 10-500 75 0.5 1.6 3.1 
  100 3.8 2.6 8.7 
  200 4.2 5.4 7.8 
Mirtazapine 5-300 10 1.0 5.6 7.7 
  50 -2.0 4.6 2.5 
  100 -5.3 5.2 3.9 
Nortriptyline 10-500 75 -2.1 2.0 1.7 
  100 3.5 3.9 8.1 
  200 3.9 3.2 7.2 
Paroxetine 5-500 10 -1.4 4.7 6.3 
  50 7.0 6.2 4.5 
  150 2.5 4.3 3.2 
Sertraline 5-300 10 11.1 1.4 7.4 
  50 0.6 3.6 1.6 
  100 -1.4 1.9 4.2 
*adapted from Frahnert et al. (2003) 
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The analytical column (250 x 4.6 mm I.D.) containing Nucleosil 100-5-Protect 1 
(endcapped), particle size 5 µm (Macherey & Nagel, Düren, Germany) was kept in a 
column oven (EchoTherm CO30, Torrey Pines Scientific LLC, Solana Beach, USA) 
maintained at 25°C. The mobile phase consisted of 25 mM potassium 
dihydrogenphosphate (pH 7.0) : acetonitrile (60:40) at a flow rate of one ml/min. The 
eluted substances were detected by a Shimadzu SPD-10AVP UV-detector (Shimadzu, 
Duisburg, Germany) at 230 nm. The acquisition and integration was performed by 
McDacq32 Software, version 1.51 (Bischoff, Leonberg, Germany). The accuracy and 
precision of the HPLC method with solid phase extraction are presented in Table 5 
(Frahnert et al. 2003). 
In Mainz plasma samples were directly injected in a pre-column for purification before 
separation by the analytical column (Härtter and Hiemke 1992a, Härtter et al. 1992b, 
Härtter et al. 1994). The chromatographic system consisted of an autosampler 231 XL 
(Gilon, Villiers Le Bel, France) equipped with a 7010 Rheodyne injection valve and a 
100 µL sample loop, a Bischoff HPLC pump 2250 (Bischoff, Leonberg, Germany), and 
an automated six-port swiching valve Rheodyne 7000 (Besta, Wilhelmsfeld, Germany). 
Detection of sertraline and paroxetine was performed with a UV detector SPD-10A 
(Shimadzu, Duisburg, Germany) at a wave length of 210 nm and with a fluorescence 
detector Shimadzu RF-10A XL (Shimadzu, Duisburg, Germany) for venlafaxine and 
desmethylvenlafaxine at 220 nm and 305 nm. Recording and integration was 
performed with the Kontron Integration Pack 3.9 (Kontron, Milano, Italy). Patients’ 
plasma samples were directly injected onto a 10 x 2.0 mm clean-up column filled with 
20 µg CN-bonded silica (MZ-Analysentechnik, Mainz, Germany) and washed with 
deionized water containing 5 % acetonitrile. The mobile phase for separation of 
sertraline and paroxetine consisted of 0.01 M dipotassium-hydrogenphosphate buffer 
(adjusted with 85% phosphoric acid to pH 6.4) : acetonitrile (1:1 vol/vol); the mobile 
phase for determination of venlafaxine an O-desmethylvenlafaxine consisted of 
triethylamine buffer (2.5 mL in 1700 mL, adjusted with 85% phosphoric acid to pH 2.5) : 
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acetonitrile (85:15 vol/vol) (Dr. Sebastian Härtter, oral communication). Patients 
evaluated with the HPLC method with direct injection received paroxetine, sertraline or 
venlafaxine. The limit of quantification was 5 ng/mL for paroxetine and sertraline and 
10 ng/mL for venlafaxine and O-desmethylvenlafaxine (Dr. Sebastian Härtter, oral 
communication). 
Internal quality control criteria of both laboratories were taken from the Guideline of the 
Bundesärztekammer (Bundesärztekammer 2002). Thus, the measured concentration 
of quality control samples should not deviate more than three times the standard 
deviation from the true concentration.  
Quality was assured follows: the chromatographic system was calibrated with standard 
curves for every antidepressant consisting of six quality controls samples prepared in 
the laboratory; in Bonn, two commerially available quality control samples (Lyphochek 
Benzo/TCA Control-Set, Bio-rad, München, Germany and ClinChek Control for 
Tricyclic Antidepressants, Recipe, München, Germany) were carried forward in 
addition. All stock solutions for calibration standards and quality control were prepared 
by dissolving 10 mg of the respective drug in 10 ml methanol. Pooled drug-free serum 
from healthy volunteers was spiked with stock solution of the drug in water (HPLC-
grade, 1:10) to achieve calibration standard concentrations. Quality control samples 
that were run in each assay, were prepared in the same way. All serum standards, 
quality control samples and stock solutions were stored in aliquots at -20°C and were 
stable for at least 3 months. In Bonn the internal standard melperone was diluted with 
serum to a concentration of 3000 ng/ml. 
When analysing patient samples, internal quality control was assured by two quality 
control samples (see high and low concentration in Table 5 and Table 6).  
In addition to internal quality control, both laboratories participated in external quality 
controls of Health Control, Cardiff. United Kingdom. It was carried out every month for 
amitriptyline, nortriptyline, imipramine, desipramine, clomipramine and 
norclomipramine, and  every  three  months  for  doxepine,  nordoxepine,  fluvoxamine, 
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Table 6. Internal quality control data for measuring antidepressants in Mainz* 
Antidepressant Plasma 
concentration  
[ng/mL] 
Relative error 
[%] 
(n = 20) 
Inter-day 
coefficient of 
variation 
[%]  (n = 20) 
Paroxetine 22 -13.6 10.1 
 105 -1.9 10.5 
Sertaline 21 -2.9 11.7 
 101 3.3 9.1 
Venlafaxine 23 10.4 10.8 
 244 2.5 6.3 
O-desmethylvenlafaxine 50 3.8 7.7 
 499 0.5 4.1 
* based on oral communication with Dr. Sebastian Härtter 
 
paroxetine, sertraline and citalopram. A comparison of the external quality control 
results showed that more than 80% of the samples did not deviate more than 20% from 
the consensus mean of all laboratories participating at Health Control. 
For mirtazapine, no external quality control was available, thus plasma concentrations 
were analysed in duplicate for this thesis. 
3.4.2 Lithium 
Lithium serum concentrations were determined by flame emission spectroscopy. This 
assay is based on thermic excitation of valence electrons and measures the 
photoenergy that is set free when returning to the ground state at a wave lengh of 
680.7 nm (Amdisen 1975).  
The flame photometer (FMC 6341 with compressor 5240, Eppendorf, Hamburg) was 
heated for 15 min before analysis and calibrated with 2 mL destilled water and 2mL  
lithium standard solution (2 mM, Eppendorf, Hamburg). Patient samples were prepared 
by mixing 100µL of plasma and 2 mL destilled water and were analysed in duplicate. In 
addition to the patient samples, two external quality control samples (Lyphocheck 
Assayed Chemistry Control Level 1, BioRad, München and Precinorm U Universal-
Kontrollserum für Lithium, Roche Molecular Biochemicals, Mannheim), and two internal 
quality control samples were analysed in duplicate. Internal quality control was carried 
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out according to the Guideline of the Bundesärztekammer (Bundesärztekammer 2002); 
measured concentrations of quality control samples should not deviate more than three 
times the standard deviation from the true concentration. Every third month, the 
laboratory participated in external quality controls of INSTAND e.V., Düsseldorf, 
Germany. 
Applying this method, the coefficient of variation within and between days was 0.8% 
and 4%, respectively, and the relative error was 3.3%. 
3.5 Genotyping 
Genomic DNA was prepared from leukocytes of 10 ml whole blood samples (Lewin and 
Steward-Haynes 1992) with a DNA Blood Isolation Kit QIAGEN-tip 500 (Qiagen GmbH, 
Germany)  according  to  the manufacturer’s  instructions.  Isolated DNA was stored at 
-20°C until genotyping was begun.  
Genotyping for CYP2C9, CYP2C19, and CYP2D6 was performed with patients’ 
genomic DNA. Amplification of the gene sequences studied was carried out by 
polymerase chain reaction (PCR, Saiki et al. 1988). Defective alleles of CYP2C9 and 
CYP2C19 were detected by restriction fragment length polymorphism (RFLP, 
Brockmöller et al. 1995). Furthermore, for CYP2D6 genotyping automated sequencing 
analysis (Cycle Sequencing, Wen 2001) was used. 
3.5.1 CYP2C9  
CYP2C9 and was done by RFLP analysis that included screening for the major 
defective alleles CYP2C9*2 and CYP2C9*3 (de Morais et al. 1994). Genomic DNA 
(300 ng) was used to amplify the CYP2C9 gene with the PCR engine T Gradient 
(Biometra, Göttingen, Germany), 1 U Taq DNA polymerase (Amersham Bioscience, 
Freiburg, Germany), 200 µM desoxyribonucleic triphosphates (Applied Biosystems, 
Darmstadt, Germany), 200 nmol forward primer and 200 nmol reverse primer 
(Interaktiva, Ulm, Germany) as stated by de Morais et al. (1994).  
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The detection of the CYP2C9*2 mutation was carried out as follows: the amplified 
fragment [375 bp] was incubated at 37°C for 18 hrs with the restriction enzyme Sau 96I 
(New England Biolabs, Frankfurt, Germany) that was specific for the sequence of the 
analysed mutation. The fragments’ size was then controlled by horizontal agarose gel 
electrophoresis (80 V, 60 min) (Meyers et al. 1976) with the Sub Cell GT gel chamber 
and the Power Pack 3000 electrophoresis system (Bio-Rad, München, Germany). The 
gel consisted of 2% peq Gold Universal Agarose (peq Lab, Erlangen, Germany). The 
comparison with a specific control DNA (Roche, Mannheim, Germany) allowed the 
detection of three fragments [177 bp, 119 bp, 79 bp] in carriers of two wild type alleles, 
two fragments [256 bp, 119 bp] in carriers of two CYP2C9*2 alleles, and four fragments 
in carriers of one wildtype and one CYP2C9*2 allele [256 bp, 177 bp, 119 bp, 79 bp]. 
For detection of the CYP2C9*3 mutation the PCR product [175] was incubated at 37 °C 
for 18 hrs with the restriction enzyme StyI (New England Biolabs, Frankfurt, Germany). 
Agarose gel electrophoresis (80 V, 90 min) as described for CYP2C9*2 reveiled one 
fragment for carriers of two wildtype alleles [137 bp], two fragments for carriers of two 
CYP2C9*3 alleles [104 bp, 33 bp], and three fragments for carriers of one wildtype and 
one defective allele [137 bp, 104 bp, 33 bp]. 
Patients were divided into carriers of none, one, or two functional alleles of CYP2C9.  
3.5.2 CYP2C19 
Genotyping of CYP2C19 screened for the major defective alleles CYP2C9*2 
(Brockmöller et al. 1995). Amplification of the CYP2C19 gene was carried out with 600 
ng genomic DNA with the PCR engine T Gradient (Biometra, Göttingen, Germany), 1 U 
Taq DNA polymerase (Amersham Bioscience , Freiburg, Germany), 100 µM 
desoxyribonucleic triphosphates (Applied Biosystems, Darmstadt, Germany), 300 nmol 
forward primer and 300 nmol reverse primer (Interaktiva, Ulm, Germany) as stated by 
Brockmöller et al. (1995).  
The amplified fragment [168 bp] was incubated at 37°C for 18 hrs with the restriction 
enzyme SmaI (New England Biolabs, Frankfurt, Germany) that was specific for the 
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sequence of the wildtype allele. The fragments’ size was then controlled by horizontal 
agarose gel electrophoresis (80 V, 90 min) (Meyers et al. 1976) with the Sub Cell GT 
gel chamber and the Power Pack 3000 electrophoresis system (Bio-Rad, München, 
Germany). The gel consisted of 2% peq Gold Universal Agarose (peq Lab, Erlangen, 
Germany). The comparison with a specific control DNA (Roche, Mannheim, Germany) 
allowed the detection of two fragments [118 bp, 50 bp] in carriers of two wild type 
alleles, one fragment [168 bp] in carriers of two CYP2C19*2 alleles and three 
fragments in carriers of one wildtype and one CYP2C19*2 allele [168 bp, 118 bp, 50 
bp]. 
3.5.3 CYP2D6 
CYP2D6 genotyping screened for the functional wildtype alleles CYP2D6*1 and 
CYP2D6*2, for the major defective alleles CYP2D6 *3, *4, *5, *6 as well as for the rare 
defective alleles CYP2D6 *7 and *8, the CYP2D6 *9 allele, that shows reduced enzyme 
activity, and gene duplication (Daly et al. 1996).  
First, a PCR from DNA samples was performed to generate a large fragment of the 
entire CYP2D6 gene [4414 bp] with the PCR engine T Gradient (Biometra, Göttingen, 
Germany), 2.63 U Expand Long Template (Roche, Mannheim, Germany), 500 µM 
desoxyribonucleic triphosphates (Applied Biosystems, Darmstadt, Germany), 300 nmol 
forward primer and 300 nmol reverse primer (Interaktiva, Ulm, Germany). Then, this 
fragment was used as a template to amplify four of the nine exons of the CYP2D6 gene 
(exon 3 [192 bp], exon 4 [202 bp], exon 5 [218 bp] and exon 6 [186 bp]) applying a set 
of nested PCRs with 1 U Taq DNA polymerase (Amersham Bioscience , Freiburg, 
Germany), 100 µM desoxyribonucleic triphosphates (Applied Biosystems, Darmstadt, 
Germany), 200 nmol forward primer and 200 nmol reverse primer (Interaktiva, Ulm, 
Germany) as previously described (Broly et al. 1995). Mutations in these amplified 
exons were screened using the cycle sequencing technique on an automated DNA 
sequencer (Model ABI 310, Applied Biosystems Inc. California, USA) under the 
following conditions: heating at 96°C for 2 min and 25 cycles (96°C for 10 sec, 60°C for 
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245 sec); the sequencing primers were those used for exon PCR, the 
didesoxyribonucleic triphosphates originated from the BigDye Cycle Sequencing Kit 
(Applied Biosystems, Darmstadt, Germany).  
The complete allele deletion (CYP2D6*5) was detected by PCR from genomic DNA 
according to the method of Steen et al. (1995). A long-PCR was carried out of 600 ng 
genomic DNA with the PCR engine T Gradient (Biometra, Göttingen, Germany), 1 U 
Expand Long Template (Roche, Mannheim, Germany), 400 µM desoxyribonucleic 
triphosphates (Applied Biosystems, Darmstadt, Germany), 200 nmol forward primer, 
200 nmol reverse primer and 200 nmol of a third primer (Interaktiva, Ulm, Germany) 
producing specific fragments of 4500 bp and 3500 bp in case of deletion of the 
CYP2D6 gene. Separation of the PCR products were achieved by horizontal agarose 
gel electrophoresis (80 V, 120 min) (Meyers et al. 1976) with the Sub Cell GT gel 
chamber and the Power Pack 3000 electrophoresis system (Bio-Rad, München, 
Germany). The gel consisted of 1% peq Gold Universal Agarose (peq Lab, Erlangen, 
Germany) and ethidiumbromide (Merck, Darmstadt, Germany). The fragments’ length 
was determined in comparison with a specific control DNA (Roche, Mannheim, 
Germany). 
Detection of CYP2D6 gene duplication was carried out by long-PCR from 750 ng 
genomic DNA. The PCR conditions were chosen as described by Løvlie et al. (1996), 
applying 1 U Expand Long Template (Roche, Mannheim, Germany), 400 µM 
desoxyribonucleic triphosphates (Applied Biosystems, Darmstadt, Germany), 300 nmol 
forward primer and 300 nmol reverse primer (Interaktiva, Ulm, Germany). Specific 
fragments of 5200 bp and 3600 bp allowed the detection of CYP2D6 gene duplication 
by agarose gel electrophoresis that was carried out as described for the detection of 
gene deletion. 
Patients were divided in carriers of none (poor metabolizer), one (intermediate 
metabolizer), two (extensive metabolizer) or more than two (ultrarapid metabolizer) 
functional CYP2D6 alleles (Lohmann et al. 2001). 
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3.6 Pharmacokinetic analysis 
3.6.1 Pharmacokinetic models 
Pharmacokinetic analysis describes the absorption, distribution and elimination of a 
drug in the body. This can be done by applying compartment models and estimating 
pharmacokinetic parameters that characterise the pharmacokinetic behaviour of a 
drug. Two different models were applied in this thesis. 
3.6.1.1 One-compartment model 
The one-compartment model was applied for mixed-effects modeling of mirtazapine. It 
describes a first-order absorption into a central compartment, characterised by the 
volume of distribution, and a first-order elimination phase that is either characterised by 
the elimination rate constant or the clearance (Figure 3). 
Central 
compartment
k01 k10
 
Figure 3. Schematic presentation of a one-compartment model 
 
( ) ( )eekkV DFkC ttdt kk ⋅−⋅− −∗−⋅ ⋅⋅= 0110100101            Equation 1 
 
kVCL d 10⋅=              Equation 2 
 
Ct  Plasma concentration at time t 
k 01  Absorption rate constant 
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k10  Elimination rate constant 
V d  Volume of distribution 
D  Dose 
F  Bioavailability 
CL  Clearance 
3.6.1.2 Two-compartment model 
The two-compartment model was used to characterize the pharmacokinetics of lithium. 
It has the same characteristics as the one-compartment-model, except that there is a 
peripheral compartment in equilibrium with the central compartment (Figure 4). The 
intercompartmental distribution follows first-order kinetics. 
Central 
compartment
k01 k10
Peripheral 
compartment
k12 k21
 
Figure 4. Schematic presentation of a two-compartment model 
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BAC +=  
( )  ⋅⋅−+++⋅= ++ kkkkkkkk 10212102112 45.0 102112α  
( )  ⋅⋅−−++⋅= ++ kkkkkkkk 10212102112 45.0 102112β  
kk 2112 ,  Distribution rate constants 
βα ,  Hybrid rate constants  
V c  Central volume of distribution 
3.6.2 Population pharmacokinetic analysis 
Population pharmacokinetic analysis was performed with the software WinNonMix, 
version 2.0.1, Pharsight Corporation, Mountain View, California. This program 
iteratively estimates the fixed effects representing the population mean 
pharmacokinetic parameters and random effects representing the inter- and 
intraindividual variability of these parameters in one step by fitting a population model 
to the data. This is different from the classical pharmacokinetic approach, where the 
data of each patient are analysed separately. The estimation of the fixed effects is 
based on generalized least squares assuming a known covariance matrix, and random 
effects are then estimated by maximising the restricted likelihood. Therefore, the 
nonlinear model function is linearised by conditional first-order Taylor expansion 
(FOCE) and an objective function is minimised that is proportional to twice the negative 
restricted log-likelihood. Individual pharmacokinetic parameters are then obtained by 
post-hoc Bayesian curve fitting (Pharsight Corporation 1999).  
To assess the factors influencing the pharmacokinetics of mirtazapine, a model for 
covariate effects was built in three steps (Mandema et al. 1992): (1) Building a basic 
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model without covariates; (2) building the final model including all relevant covariates; 
and (3) assessing the appropriateness of the model. 
3.6.2.1 Basic model building 
The mixed effects model consists of a structural, a statistical, and a covariate model. 
Building the basic model means choosing the appropriate structural and statistical 
model. 
Concerning the structural model, a one- and a two-compartment model with first-order 
absorption were tested. The two-compartment model was tested, because it was used 
previously to describe mirtazapine pharmacokinetics (Voortman and Paanakker 1995). 
The one-compartment model was tested to keep the model as simple as possible since 
only trough levels were available and this fact might prevent estimation of the 
distribution parameters. It was tried to estimate the pharmacokinetic parameters by the 
WinNonMix™ software or to fix them according to previously published data to stabilise 
the estimation process. 
The statistical model accounts for interindividual and residual variability. Variability is 
usually assumed to follow normal distribution with a mean of zero. The interindividual 
variability (η) is described as the individual’s deviation from the population mean (Θp) of 
a kinetic parameter. As individual pharmacokinetic parameters (Θi) are usually log-
normally distributed, the interindividual variability was included in exponential form in 
the model:  
epi η⋅= ΘΘ           Equation 4 
The residual variability accounts for the precision of the analysis of plasma 
concentrations, variations in time of drug intake or blood withdrawal and other system-
related variations. 
The residual error (ε) can be included in the model as a constant parameter (additive 
error, equation 5), a constant proportion (multiplicative error, equation 6) or a 
combination of both (equation 7). Each possibility was tested for the basic model.  
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12 ⋅=σε  Equation 5
C
aˆ2 ⋅=σε  Equation 6



 +⋅= C
bˆ2 ασε  Equation 7
σ 2  Variance of the residual error 
ba,  Constants 
Cˆ  Predicted plasma concentration 
 
A model was judged reliable when (1) convergence was achived within the estimation 
process, (2) when the 95% confidence interval of the estimated parameter’s standard 
error did not include zero, (3) when no covariance of the random effects was noted, 
and (4) when the Akaike information criterion (AIC) decreased after inclusion of an 
additional parameter. 
3.6.2.2 Final model building  
Covariates that influence the pharmacokinetic parameters of a drug can be introduced 
in the mixed-effects specification by additional fixed effects (Θ1, Θ2,…, Θn) representing 
a shift parameter or a multiplier associated with the specific covariate.  
Initial screening included diagnostic plots of possible covariates versus the individual’s 
η’s that were estimated from the basic model and stepwise multiple linear regression 
analysis of this parameter, performed with SPSS®, version 10.0, SPSS inc., Chicago, 
Illinois. These covariates were then included in a stepwise forward method into the 
mixed-effects specification. A parameter was judged relevant if (1) convergence was 
achieved within the estimation process (2), if the 95% confidence interval of the 
estimated parameters’ standard error did not include zero, (3) if the difference between 
the groups of categoric covariates was estimated at least 10%, (4) if the interindividual 
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variability was reduced, and (5) if there was a drop in the objective function value 
between two nested models of at least 3.84. The latter corresponded to p < 0.05 in the 
log-likelihood ratio test, assuming that the difference in the objective function values 
was χ2-distributed (NONMEM Project Group 1994). 
3.6.2.3 Model check 
To assess the goodness-of-fit of the final model plots of observed trough plasma 
concentrations versus predicted plasma concentrations were examined. They should 
show high correlation. The weighted residuals of predicted plasma concentrations were 
plotted against the predicted concentrations and against time; they should be randomly 
distributed around zero. Histograms of individuals’ η’s should be normally distributed 
with a mean of zero.  
3.6.3 Bayesian curve fitting 
Bayesian curve fitting was applied to estimate individual plasma concentrations, taking 
into account the mean and the distribution of pharmacokinetic parameters within a 
standard population and measured individual plasma concentrations at the same time. 
The pharmacokinetic model is fitted to the data by iteration and minimising a target 
objective function (Φ):  
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Equation 8 
Ci  Ith measured concentration 
Ciˆ  I
th predicted concentration 
P j  Population mean of the j
th normally distributed pharmacokinetic parameter 
Pjˆ
 Jth predicted normally distributed parameter 
Pk  Population mean of the k
th log-normally distributed parameter 
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Pkˆ  K
th predicted log-normally distributed pharmacokinetic parameter 
σˆ i  Standard deviation of the ith predicted concentration 
σˆ j  Standard deviation of the jth predicted normally distributed pharmacokinetic parameter 
σˆ k  Standard deviation of the kth log-normally distributed pharmacokinetic parameter 
N Number of measured concentrations 
M Number of normally distributed pharmacokinetic parameters 
K Number of log-normally distributed pharmacokinetic parameters 
 
3.6.3.1 Establishment of a service for lithium dose individualisation by Bayesian curve 
fitting 
The computer-assisted dose individualisation was established by extending the 
Abottbase pharmacokinetic software®, version 1.10, Abbott GmbH Diagnostika, 
Delkenheim, Germany.  
The lithium specification was based on a literature search and included population 
pharmacokinetic parameters of a two-compartment model as well as covariates 
influencing the pharmacokinetics of lithium. For further analysis, co-medication with 
ACE-inhibitors, calcium antagonists and β receptorantagonists were combined in one 
covariate called “antihypertensives”. The covariate “diuretics” included thiazides and 
loop diuretics and the covariate “nonsteroidal antiinflammatory drugs” (NSAID) 
summarised co-medication with diclofenac and indometacine. “Obesity” included 
patients with a body mass index (BMI) of 30 or higher. The BMI is calculated by 
dividing the body weight in kilograms by the squared height in metres. Patients over 70 
years of age were considered “elderly”. The creatinine clearance was calculated 
according to Cockcroft and Gault (1976). The lithium specification is detailed in Table 
7. 
The method was validated with serum concentrations from routinely monitored 
inpatients that were retrospectively evaluated.  One to eight  serum concentrations per  
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Table 7. Lithium specification in the Abottbase pharmacokinetic software®  
Parameter Population mean Reference 
Clearance (CL)                                 
[L / hr / 70kg] 
1.5                  
(Range: 3.47-27.75) 
Taright et al. 1994 
Variability of CL [%] 38% Taright et al. 1994 
Central volume of distribution (Vc)    
[L / 70kg] 
10.55               
(Range: 3.47-27.75) 
Taright et al. 1994 
Variability of Vc  [%] 51% Taright et al. 1994 
Distribution rate constants [hr-1]       
k12                                       
               
               k21 
                            
0.49                
(Range: 0-1.95) 
1.11                
(Range: 0.03-2.5) 
Taright et al. 1994 
Absorption rate constant [hr-1] 0.29 Taright et al. 1994 
Bioavailability [%]                  
Quilonum retard®     
Hypnorex retard® 
                              
0.85                        
0.95 
                     
Manufacturers’    
information  
Correction factors for: 
Antihypertensives 
                               
CL x 0.75 
                                     
Sihm et al. 2000        
Krusell et al. 1997    
Sproule et al. 2000 
Diuretics CL x 0.5 Sproule et al. 2000      
Sihm et al. 2000 
Nonsteroidal anti-
inflammatory drugs  
CL x 0.8 Turck et al. 2000   
Reimann & Fröhlich 1981 
Creatinine clearance  CL = 0.235 x CLcrea Pepin et al. 1980 
Obesity CL x 1.47                 
Vc x 0.64 
Reiss et al. 1994 
Old age CL x 0.4                   
Vc x 0.77 
Sproule et al. 2000 
 
patient were available for Bayesian curve fitting using the extended Abbottbase 
pharmacokinetic software®. Covariates were included if they reduced the residual sum 
of squares of the fit. To evaluate the predictive performance of the model, the accuracy 
and precision to predict the last observation of every patient was compared with three 
a-priori methods for dose individualisation (Pepin et al. 1980; Jermain et al. 1991; 
Yukawa et al. 1993). 
3.6.3.2 Predictive performance 
The predictive performance of the methods for lithium dose individualisation was 
assessed by calculating the mean prediction error (MPE) and the mean squared error 
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(MSE) representing accuracy and precision (Sheiner and Beal 1981). The closer the 
calculated error to zero the better the predictive performance. The corresponding 
equations are: 
∑
=
−=
n
i
ii CCnMPE 1 )(
1 ˆ  Equation 9
∑ −
=
=
n
i
CC iinMSE 1
2)ˆ(1  Equation 10
Ci  ith measured concentration 
Ciˆ  
ith predicted concentration 
n  Number of concentrations 
3.6.3.3 Method of Pepin and colleagues (1980) 
Pepin and colleagues assumed the pharmacokinetics of lithium to follow a one-
compartment model and the lithium clearance to amount 23.5% of the creatinine 
clearance. Consequently, they defined the trough serum concentration to equal 
( )τ
τ
⋅−
⋅−
−⋅
⋅=
10
10
1 kd
k
eV
eDCP         Equation 11 
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=
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1
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t   and  235.0⋅= CreaCLCL  
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⋅−=
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140
 and maleCrea
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Crea CLCL ⋅= 85.0  
where  
( )
54.2
4.1523.250 −⋅+= heightIBWmale   
and  
( )
54.2
4.1523.25.45 −⋅+= heightIBW female  
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CP  Predicted trough serum concentration (mmol/L) 
τ  Dosing interval (h) 
k10  Elimination rate constant (h-1) 
V d  Volume of distribution (L) 
D  Dose (mmol) 
t 21  Half-life (h) 
CL Crea  Creatinine clearance (mL/min) 
CL Clearance of lithium (mL/min) 
SCrea  Serum creatinine concentration(mg/dL) 
IBW  Ideal body weight (kg) 
3.6.3.4 Method of Yukawa and colleagues (1993) 
Yukawa and colleagues developed a population pharmacokinetic model by mixed 
effects modeling by retrospectivly analysing 303 serum concenrtations of 90 patients 
from routine serum concentration monitoring. They applieda one-compartment model 
to the data and found serum creatinine, total body weight and age above or below 50 
years to predict the lithium clearance. 
CL
DCP =          Equation 12 
where  
Crea
age S
weightCL 79.7225.06.3150
−⋅+=<  
and  ( )50634.0
79.7225.06.3150 −⋅−
−⋅+=≥ ageS
weight
Crea
ageCL  
CP  Predicted serum trough concentration (mmol/L) 
D  Dose (mmol/day) 
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CL  Clearance of lithium (L/day) 
CreaS  Serum creatinine concentration (mg/dL) 
3.6.3.5 Method of Jermain and colleagues (1991) 
Similar to Yukawa and colleagues, Jermain and colleagues developed a population 
pharmacokinetic model for lithium by mixed effects modeling by analysing the data of 
79 inpatients from routine drug monitoring. They used a one-compartment model and 
found the creatinine clearance (calculated according to Cockcroft and Gault (1976)) 
and the lean body weight to be significant covariates on lithium clearance. 
CL
DCP =           Equation 13 
where  ( ) ( )CreaCLLBWCL ⋅+⋅= 0885.00093.0  
where  
( )
Crea
male
Crea S
weightageCL ⋅
⋅−=
72
140
  
male
Crea
female
Crea CLCL ⋅= 85.0  
and  
2
1281.1 


⋅−⋅=
height
weightweightLBW male  
and  
2
14807.1 


⋅−⋅=
height
weightweightLBW female  
CP  Predicted serum trough concentration (mmol/L) 
D  Dose (mmol/day) 
CLCrea  Creatinine clearance (L/h) 
CL  Clearance of lithium (L/h) 
CreaS  Serum creatinine concentration (mg/dL) 
LBW  Lean body weight (kg) 
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3.7 Statistical analysis 
3.7.1 Descriptive statistics and hypothesis testing 
The characteristics of a sample were described by the arithmetric mean and the 
relative standard deviation for continuous and normally distributed data as well as by 
the median and range. 
The one-sample Kolmogorov-Smirnov test was applied to check wether the distribution 
of a sample was in accordance with a normal distribution. A p < 0.05 indicated a 
significant difference between the two distributions. 
χ2-testing was used to check wether the frequencies of categories within two 
populations were significantly different from each other (p < 0.05). 
3.7.2 Correlation and regression 
Correlation analysis was carried out to check the extent to which two variables were 
related to another. The Spearman’s correlation coefficient (rS) was used because in this 
thesis ordinal data or data that were not normally distributed were analysed. The 
correlation coefficient can be between –1 and 1: 0, no correlation, –1 and 1, complete 
negative and positive correlation, respectively. 
Regression analysis was applied to describe a functional relationship between a 
dependent variable and several covariates.  
Stepwise multiple linear regression was used for continuous dependent variables and 
continuous, ordinal or dichotomous covariates. Covariates were introduced in the linear 
model in a stepwise forward manner checking the significance of an improved fit after 
inclusion and exclusion of each covariate. The goodness-of-fit was assessed by the 
coefficient of determination (r2) that is the closer to 1, the better the model 
approximates linearity. 
The functional relationship is described as: 
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xbxbxby nn ⋅++⋅+⋅+= ...2211α        Equation 14 
y  Dependent variable 
a  Intercept 
x n,...,2,1  Covariates 
b n,...,2,1  Regression coefficients 
If the calculated r2 and b1,2,…,n differ significantly (p < 0.05) from 0 by the statistical test 
parameters of F or T, a covariate is included in the linear model. The underlying 
statistical procedures are analysis of variance (ANOVA) or Student’s t-test.  
Logistic regression was carried out on dichotomous dependent variables. Covariates 
were introduced in a stepwise forward manner. In this procedure, the probability of one 
of the two events was calculated by: 
e z
p −+= 1
1
         Equation 14 
where  xbxbxbz nn ⋅++⋅+⋅+= ...2211α  
z  Dependent dichotomous variable 
p  Probability  
a  Intercept 
x n,...,2,1  Covariates 
b n,...,2,1  Regression coefficients 
A variable is included in the logistic regression model if the computed b1,2,…,n differ 
significantly from 0 (p < 0.05) by χ2-testing according to Wald. The Odds Ratio 
represents the dependent variable’s relative risk for one of two events compared to the 
other event in predefined populations. It is calculated by: 
ff
ff
OR
2112
2211
⋅
⋅=           Equation 15 
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f 11  Number of individuals with event 1 in group 1  
f 12  Number of individuals with event 1 in group 2 
f 21  Number of individuals with event 2 in group 1 
f 22  Number of individuals with event 2 in group 2 
3.7.3 Receiver operating curve 
The receiver operating curve was used to describe the ability to classify patients into 
responders or nonresponders with respect to antidepressant treatment by their mean 
trough plasma concentration. 
The specifity is plotted versus 1 minus the sensivity of this prediction. A parameter 
used to predict and event should be as specific and precise as possible (Bühl and Zöfel 
2002). Thus, the predicted coordinates of the curve were used to define a threshold 
concentration with the best sensitivity and specifity by plotting the difference between 
specifity and 1 minus sensitivity against the mean trough plasma concentration. 
3.7.4 Goodness-of-fit 
Goodness-of-fit parameters are commonly based on the minimisation of the sum of 
least squares (ss).  
( )∑∑ −== 2ˆiii CCSS ε          Equation 16 
The Akaike information criterion (AIC) evaluates the goodness-of-fit by taking into 
account the number of parameters in the model (Yamaoka et al. 1978). It is calculated 
according to the following formula: 
PssNAIC ⋅+⋅= 2)ln(          Equation 17 
AIC Akaike information criterion  
N Number of plasma concentrations 
ss Sum of least squares 
P Number of model parameters 
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4 Results 
4.1 Impact of CYP2C9, CYP2C19 and CYP2D6 genotypes on treatment 
outcome  
4.1.1 Patient characteristics 
The entire dataset for analysis of the impact of CYP2C9, CYP2C19 and CYP2D6 on 
treatment outcome consisted of 875 observations of 136 patients. Twenty-five patients 
were recruited in Mainz and received sertraline, venlafaxine or paroxetine. One patient 
was treated in Gabersee and received doxepin followed by venlafaxine. In addition, 
110 patients were recruited in Bonn and treated with citalopram, mirtazapine, 
amitriptyline, sertraline, doxepin, fluvoxamine, clomipramine or paroxetine. From these 
data, patients were selected according to predefined criteria (see section 3.1.1.1) to 
evaluate the relationship between genotype, trough plasma concentration, response, 
and side effects. The frequencies of antidepressants within the three subsets is 
summarised in Table 8. 
Table 8. Frequencies of antidepressants in the analysis of the relationship 
between genotype and treatment outcome * 
 All 
observations 
 
Subset for 
concentration 
evaluation 
Subset for 
response 
evaluation 
Subset for 
side effect 
evaluation 
Amitriptyline 9 / 44 3 / 29 4 / 27 6 / 6 
Citalopram 50 / 333 47 / 295 41 / 301 50 / 50 
Clomipramine 2 / 2 0 / 0 0 / 0 0 / 0 
Doxepin 4 / 18 4 / 17 3 / 17 4 / 4 
Fluvoxamine 1 / 5 1 / 5 0 / 0 1 / 1 
Mirtazapine 43 / 249 43 / 238 33 / 215 41 / 41 
Paroxetine 5 / 25 6 / 22 3 / 18 4 / 4 
Sertraline 14 / 90 14 / 79 9 / 82 14 / 14 
Venlafaxine 17 / 109 15 / 75 12 / 91 16 / 16 
*Number of patients per number of observations 
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Table 9. Patient characteristics for evaluation of the impact of genotypes on 
trough plasma concentrations  
Age [years] **  49 (14) 
Gender *     Female          
Male 
78                          
58 
Height [cm] **  170 (9) 
Patients’ mean weight [kg] **  76.3 (17.5) 
Deviation of mean dose-corrected trough 
plasma concentration from the substance-
specific median [%] ** 
                                 
17.1 (80.8) 
Patients’ mean number of substrates of: ** # CYP1A2  
CYP2C9 
CYP2C19 
CYP2D6  
CYP3A4 
0.10 (0.27)          
0.20 (0.44)           
0.16 (0.36)           
0.27 (0.45)           
0.68 (0.72) 
Patients’ mean number of inhibitors of: ** # CYP2C9     
CYP2C19 
CYP2D6   
CYP3A4 
0.03 (0.16)           
0.07 (0.26)          
0.08 (0.23)          
0.68 (0.72) 
Patients’ mean number of inducers of: ** # CYP1A2   
CYP2C9 
CYP2C19 
CYP3A4 
0.09 (0.01)          
0.03 (0.16)          
0.03 (0.16)          
0.05 (0.20) 
Patients’ mean consumption of: ** # Coffee + 
Cigarettes + 
Alcohol + 
0.92 (0.46)          
0.74 (0.90)          
0.18 (0.37) 
*expressed as numbers of subjects within the specific category  
**expressed as mean (standard deviation) 
#calculated over the patients’ entire observation period 
+for definition refer to section 3.1.1.1 
 
The patients for evaluation of the impact of genotypes on plasma concentrations were 
selected according to the criteria detailed in section 3.1.1.1. The analysis included 760 
trough plasma concentrations of 136 patients (Table 9).  
Thirty-two observations were excluded since plasma concentrations or doses were 
missing or steady-state was not reached. Eighty-three observations were excluded 
because they were carried out on a second antidepressant that was administered to 
some patients within the course of the study. 
Patients for evaluation of the impact of genotypes on treatment response were selected 
according to the criteria defined in section 3.1.1.1. These data consisted of 112 
patients (Table 10). 
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Table 10. Patient characteristics for evaluation of the impact of genotypes on 
treatment response  
Age [years] **  50 (14) 
Gender * Female                      
Male 
62                            
50 
CYP2C9 genotype * PM                                
IM                                
EM 
3                              
32                            
76 
CYP2C19 genotype * PM                                
IM                                
EM 
5                              
26                            
81 
CYP2D6 genotype * PM                                
IM                                
EM                                
UM 
5                              
38                            
66                            
3 
Subtype of depression * Unipolar                 
Bipolar                
Dysthymia                 
Brief recurrent 
101                          
9                              
1                              
1 
Mean duration of observation [weeks] **  6.7 (2.4) 
HAMD total score at first rating **  23.9 (6.0) 
Relative reduction of HAMD score from the 
first to the last observation [%] ** 
 24.5 (38.8) 
Patients’ mean number of: ** # Benzodiazepines 
Hypnotics 
Antipsychotics     
Mood stabilisers  
Other antidepressants 
0.43 (0.44)         
0.17 (0.33)         
0.14 (0.29)         
0.14 (0.35)        
0.18 (0.30) 
*expressed as numbers of subjects within the specific category 
**expressed as mean (standard deviation) 
#calculated over the patients’ entire observation period  
PM = poor metabolizers, IM = intermediate metabolizers, EM = extensive metabolizers,  
UM = ultrarapid metabolizers 
 
The evaluation of the impact of genotypes on side effects was carried out on relevant 
side effects reported at all patients’ first observation after the start of antidepressive 
treatment (for definition refer to 3.1.1.1). Co-medication was stratified according to its 
clinical effects to control for interferences (Table 11). 
As the majority of patients were treated with antidepressants possessing pronounced 
serotonergic activity, a further subanalysis on serotonergic side effects was carried out 
among 85 patients treated with SSRIs or venlafaxine. Therefore, the sum of the 
following  UKU  items  was evaluated  at  the patient’s  first observation:  concentration 
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Table 11. Co-medication at the first observation from patients evaluated for the 
impact of genotypes on side effects 
 Median Range 
Number of co-medicated drugs   
causing sedation                                   
causing serotonergic effects                 
causing anticholinergic effects              
causing agitation                             
influencing blood pressure                  
influencing the gastro-intestinal system 
1                 
0                 
0                 
0                
1                 
0  
0 – 4           
0 – 2           
0 – 2           
0 – 2           
0 – 5           
0 – 2 
 
difficulties, confusion, failing memory, inner unrest, tremor, sweating, diarrhoea, and 
nausea. These items were selected according to Sternbach (1991). 
4.1.2 Genotype distributions 
Genotyping detected the funtional wildtype alleles CYP2C9*1, CYP2C19*1, CYP2D6*1 
and *2, the main defective alleles CYP2C9*2 and *3, CYP2C19*2, CYP2D6*3, *4, *5, 
*6, *9 and CYP2D6 gene duplication. χ2-testing for CYP2C9 and CYP2C19 showed no  
 
Table 12. Allele frequencies among psychiatric patients and control groups 
                   
CYP2C9 allele 
Psychiatric patients          
(n=270) 
Nonpsychiatric patients 
(n=1122) (Taube et al. 2000) 
 n % n % 
*1 223 82 944 84 
*2 26 9.6 119 11 
*3 21 7.7 59 5 
                 
CYP2C19 allele 
Psychiatric patients          
(n=272) 
Healthy volunteers         
(n=280) (Xie et al. 1999) 
*1 229 84.2 238 85 
*2 43 15.8 42 15 
                  
CYP2D6 allele 
Psychiatric patients          
(n=272) 
Healthy volunteers           
(n=390) (Griese et al. 1998) 
*1 or *2 203 74.6 285 73.0 
*3 6 2.2 4 1.0 
*4 41 15.1 76 19.5 
*5 8 2.9 17 4.3 
*6 3 1.1 5 1.3 
*7 0 0 1 0.3 
*8 0 0 1 0.3 
*9 7 2.6 0 0 
*16 0 0 1 0.3 
Duplication 4 1.5 6 3.1 
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Figure 5. Comparison of the CYP2C9 genotype distribution of our psychiatric patients 
with the control group described by Taube et al. (2000) 
 
significant difference with respect to allele frequencies (CYP2C9:  χ2=3.578, df=2, 
p=0.167 and CYP2C19: χ2=0.140, df=1, p=0.709) when compared to other Caucasian 
control groups reported in the literature (Taube et al. 2000, Xie et al. 1999). Combining 
the rare alleles CYP2D6*7, *8, *9 and *16 in one group, there was a significant 
difference in the allele fequencies between our patients and 195 healthy volunteers 
investigated by Griese et al. (1998) (χ2=19.578, df=6, p=0.003) (Table 12).  
 
           Poor                        Intermediate                    Extensive         
       metabolizer                  metabolizer                   metabolizer 
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Figure 6. Comparison of the CYP2C19 genotype distribution of our psychiatric patients 
with the control group described by Xie et al. (1999) 
 
According to the functionality of the detected CYP2D6 alleles the CYP2D6*1, *2 and *9 
alleles were combined as functional wildtype alleles and CYP2D6*3, *4, *5, *6, *7, *8 
as defective alleles without enzyme activity. There was a significant difference in the 
CYP2D6 genotype distribution between healthy volunteers and patients (χ2=7.836, 
df=3, p=0.05): poor metabolizers of CYP2D6 were underrepresented among the 
patients (Figure 7). 
Similar to the allele distributions there was no significant difference in the number of 
carriers  of  none,  one  or  two  functional  CYP2C9  or  CYP2C19  alleles  ( CYP2C9:  
          Poor                         Inter e i t                    Extensiv          
       metabolizer                   etaboliz r                  
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Figure 7. Comparison of the CYP2C19 genotype distribution of our psychiatric patients 
with the control group described by Griese et al. (1998) 
 
χ2=1.617, df=2, p=0.445; CYP2C19: χ2=0.331, df=2, p=0.847) (Figure 5 and Figure 6). 
Thus, the CYP2C9 and CYP2C19 genotype distributions were in line with previous 
findings. 
4.1.3 Relationship between genotype and trough plasma concentrations 
Stepwise multiple regression analysis was carried out on the relative deviation of 
patients’ mean dose-corrected trough plasma concentrations from the substance-
specific median. Covariates were the influence of CYP2C9, CYP2C19 and CYP2D6 
genotypes as well as gender, age, height, mean weight, coffee, alcohol and cigarette 
consumption, study centre, mean number of substrates, inhibitors or inducers of 
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The final model included 
CYP2D6 poor metabolizers (regression coefficient b = 108.985, T = 3.576, p < 0.001), 
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co-medication with CYP2D6 inhibitors (b = 102.774, T = 3.751, p < 0.001), CYP2C19 
extensive metabolizers (b = -40.260, T = -2.877, p = 0.005) and smoking (b = -15.278, 
T = -2.160, p = 0.033). Inclusion of these covariates explained 23.1% of the dependent 
variable’s variability (df=4 ; F=9.614; p<0.001), the corrected R2 was 0.207. Thus, the 
relative deviation of mean dose-corrected plasma concentrations from the substance-
specific median was significantly higher in CYP2D6 poor metabolizers or patients with 
co-medication inhibiting CYP2D6, and was significantly lower in CYP2C19 extensive 
metabolizers and smokers. 
4.1.4 Relationship between genotype and treatment response 
According to the HAMD-based response criterium, 48 patients (42.9%) were defined as 
responders and 37 patients (33%) were responders based on the CGI. These two 
response criteria were significantly correlated (rS=0.73, p<0.01); 32 patients (28.6%) 
being responders according to both criteria. Besides the genotypes of CYP2C9, 
CYP2C19 and CYP2D6, logistic regression analysis tested for the following covariates 
that putatively influenced treatment response: Gender, age, diagnosis, antidepressant, 
study centre, HAMD score at first observation, length of observation, relative deviation 
of mean dose-corrected plasma concentrations from the substance-specific median 
and mean number of co-medication with benzodiazepines, hypnotics, antipsychotics, 
mood stabilisers or other antidepressants. 
When the HAMD-defined response was evaluated by logistic regression analysis, the 
HAMD score at first observation had a significant impact on treatment response at the 
last observation (χ2=6.854, df=1, p=0.009, Odds Ratio=1.094 (95% confidence interval 
1.023-1.171). Neither the CYP2C9 genotype, nor CYP2C19 or CYP2D6 genotypes had 
an impact on the HAMD-defined response (χ2=0.504, df=1, p=0.478; χ2=0.645, df=1, 
p=0.422 and χ2=0.131, df=1, p=0.717, respectively).  
Evaluating the CGI-defined response, the mean number of co-medicated 
antidepressants and benzodiazepines were found to be significant covariates for the 
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prediction of response (χ2=4.116, df=1, p=0.042, Odds Ratio=0.148 (95% confidence 
interval 0.023-0.937) and χ2=4.195, df=1, p=0.041, Odd’s Ratio=0.362 (95% 
confidence interval 0.137-0.957) respectively). No influence was seen for the CYP2C9 
genotype (χ2=0.552, df=1, p=0.457), the CYP2C19 genotype (χ2=0.000, df=1, p=0.991) 
or the CYP2D6 genotype (χ2=0.172, df=1, p=0.678).  
An additional test was carried out to evaluate, if trough plasma concentrations below 
the limits currently used in routine drug monitoring, were associated with treatment 
response. These thresholds were 30 ng/mL for citalopram or mirtazapine, 20 ng/mL for 
sertraline, 40 ng/mL for paroxetine, 50 ng/mL for the sum of doxepin and 
desmethyldoxepin, 80 ng/mL for the sum of amitriptyline and nortriptyline and 195 
ng/mL for the sum of venlafaxine and norvenlafaxine as outlined by the Consensus 
Group on therapeutic drug monitoring of the Arbeitsgemeinschaft für Neuropsychologie 
und Psychopharmakologie (AGNP) (personal communication). Response was not 
significantly different in patients with mean trough plasma concentrations above or 
below these thresholds when defined according to the HAMD (χ2=0.001, df=1, 
p=0.982), but a trend was detected when response was defined according to the CGI 
(χ2=3.018, df=1, p=0.082). 
4.1.5 Relationship between genotype and side effects 
Relevant side effects at first observation were experienced by 52 of the 136 patients. 
The influence of the CYP2C9, CYP2C19 and CYP2D6 genotypes on the occurrence of 
relevant side effects in the entire subset was tested by logistic regression analysis 
(CYP2C9: χ2=1.156, df=1, p=0.283; CYP2C19: χ2=0.847, df=1, p=0.357; CYP2D6: 
χ2=0.283, df=1, p=0.595). Other covariates were: Gender, age, study centre, relative 
deviation of the dose-corrected plasma concentration to the substance-specific median 
and co-medication affecting blood pressure or the gastro-intestinal system, causing 
sedation, agitation, anticholinergic or serotonergic side effects. No covariate influenced 
the occurrence of relevant side effects. 
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Patients treated with SSRIs or venlafaxine (n=85) were then analysed separately for a 
relationship between genotypes and the severity of serotonergic side effects. No 
impact of genotypes was found but the severity of serotonergic side effects was linked 
to sedative co-medication (b = 0.703, T = 1.999, p = 0.049). The rating of the severity 
of serotonergic side effects turned out to be different among the study centres (b = -
0.419, T = -3.974, p < 0.001). These findings were obtained by stepwise multiple linear 
regression analysis (corrected R2 = 0.247) including the same covariates as for logistic 
regression analysis. 
 
4.1.6 Plasma concentrations and clinical outcome of poor metabolizers and 
ultrarapid metabolizers 
Clinical data of poor metabolizers of CYP2C9, CYP2C19 and CYP2D6 and ultrarapid 
metabolizers of CYP2D6 are given in Table 13. All poor metabolizers of CYP2C9 were 
inconspicious with respect to trough plasma concentrations or side effects. Two poor 
metabolizers of CYP2C19 showed dose-corrected plasma concentrations that were 
more than twice higher than the substance-specific median: one patient received 100-
225 mg amitriptyline in combination with propranolol, digoxine, valproate and nifedipine 
or amlodipine; the other patient received 75 mg sertraline in combination with folic acid. 
The mean dose-corrected plasma concentration of one of the CYP2D6 poor 
metabolizers was 678% higher than the substance-specific median. This patient took 
150 mg venlafaxine in combination with mirtazapine and zopiclon or later on with 
risperidone and pipamperone. Although both, risperidone and pipamperone, are also 
substrates of CYP2D6, trough plasma concentrations before and after initialisation of 
these drugs were equally high. Initially, five out of the six CYP2D6 poor metabolizers 
experienced relevant side effects. 
  
 
Table 13. Treatment response and side effects of poor metabolizers and ultrarapid metabolizers * 
 Drug Deviation from median 
dose-corrected trough 
plasma concentrations  
Relative drop of 
HAMD from first to 
last observation 
Absolute drop of 
CGI1 from first to 
last observation 
CGI2 at last 
observation 
Relevant side 
effects at first 
observation 
CYP2C9  Citalopram -25% -79% 0 4 No 
PM Venlafaxine 0% 61% 0 3 Yes 
 Mirtazapine -41% n.a. n.a. n.a. No 
 Mirtazapine -39% 22% 1 4 Yes 
CYP2C19  Sertraline 188% 48% 1 4 No 
PM Amitriptyline 133% 50% 2 3 No 
 Citalopram 64% 5% 1 3 Yes 
 Sertraline 36% 0% 0 4 Yes 
 Paroxetine 88% -67% 0 4 No 
CYP2D6  Doxepin -12% 59% 2 3 Yes 
PM Citalopram 70% 75%  4 2 Yes 
 Mirtazapine 28% 24% 2 3 No 
 Citalopram 39% -35% 0 4 Yes 
 Sertraline -67% n.a. n.a. n.a. Yes 
 Venlafaxine 674% -5% 0 4 Yes 
CYP2D6  Amitriptyline 6% n.a. n.a. n.a. No  
UM Sertraline -52% 65% 2 3 No 
 Venlafaxine -36% 83% 1 2 Yes 
 Mirtazapine 4% 42% 2 3 Yes 
n.a. not analysed for response       *PM= poor metabolizers, IM= intermediate metabolizers, EM= extensive metabolizers, UM= ultrarapid metabolizers 
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4.2 Therapeutic range and population pharmacokinetic analysis of 
mirtazapine  
4.2.1 Patient characteristics  
Sixty-five patients were recruited who received mirtazapine. From these patients, 327 
trough plasma concentrations were analysed. The length of observation among these 
patients  was determined  by  either  the limit  of  ten weeks  that was set  by the  study  
 
Table 14. Characteristics of patients treated with mirtazapine 
 Entire data Subgroup for response evaluation 
Patients * 65 45 
Male              28 Male                      21 Gender * 
Female          37 Female                  24 
Age [years] ** 49.2 (13.4) 49.7 (12.9)  
HAMD0 * 23.7 (6.0) 24.4 (6.09) 
HAMDend * 17.5 (8.7) 17.9 (9.0) 
Observation duration [days] ** 28 (18) 38 (16 
F 3     
Moderate 
35 F 3           
Moderate 
           
23 
Severe 22 Severe 19 
F 4 5 
ICD-10 diagnosis at the end of 
study * 
Other 3 
F 4 3 
Observations * 327 247 
Daily dose [mg] ** 37.3 (8.6) 37.6 (8.7) 
Plasma concentration [ng/mL] ** 31.7 (16.3) 32.9 (15.8) 
UKUglobal at first observation ** 1.03 (0.75) 0.86 (0.70) 
UKUsedation at first observation ** 0.94 (0.94) 1.02 (0.90) 
UKUincreased sleep at first observation **0.30 (0.64) 0.34 (0.73) 
UKUweight gain at first observation ** 0.44 (0.81) 0.24 (0.62) 
Benzodiazepines 1 126Benzodiazepines  94 
Hypnotics  47 Hypnotics  46 
Mood Stabilisers  24 Mood Stabilisers   0 
Antipsychotics  19 Antipsychotics  13 
Psychiatric co-medication per
observation * 
Antidepressants  28 Antidepressants   0 
* expressed as number within a specific category 
**expressed as mean (standard deviation) 
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protocol (7.7%), the discharge from hospital due to the patient’s recovery (58.5%), 
change of antidepressive medication (30.8%) because of partial response or 
nonresponse or due to mirtazapine-induced eczema (one case). All data were 
analysed for the relationship between mirtazapine trough plasma concentration and 
side effects (Table 14). In addition, the side effects of 32 observations that were carried 
out within the initial seven days of mirtazapine treatment were analysed separately. 
Subgroups were defined for evaluation of the plasma concentration-response 
relationship and for analysing factors influencing mirtazapine pharmacokinetics. 
For evaluation of the relationship between mirtazapine trough plasma concentrations 
on treatment response, 45 patients were selected according to the criteria stated in 
section 3.1.1.2 (Table 14). 
Patients for population pharmacokinetic analysis were selected according to the criteria 
defined in section 3.1.1.2. Out of the 327 trough plasma concentrations, seven were 
excluded because of missing dosing schedule, noncompliance (as stated by the patient 
or the hospital staff), or interference in the analytical assay. From this database we 
selected 260 observations with constant co-medication for population pharmacokinetic 
analysis. A subset of 49 patients, which included 213 observations gave written 
informed consent for genetic analysis. We determined the genotypes of CYP2C9, 
CYP2C19 and CYP2D6 of these patients (Table 15). 
4.2.2 Therapeutic range  
The relationship between mirtazapine dose and trough plasma concentration was 
assessed by computing Spearman coefficient of correlation because dose and plasma 
concentration were not normally distributed. A weak correlation between dose and 
trough plasma concentration was found (rS = 0.365, p < 0.01). There was marked 
variability of the plasma concentrations ranging from 6-29 ng/mL, 0-73 ng/mL, 0-98 
ng/mL and 14-76 ng/mL, when doses of 15, 30, 45 and 60 mg/day, respectively were 
administered (Figure 8). 
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Table 15. Characteristics of patients selected for population pharmacokinetic 
analysis of mirtazapine 
  Entire data with 
constant co-
medication 
Data of 
genotyped 
patients 
Age [years] **  49.6 (13.5) 48.7 (13.2) 
Mean weight per patient [kg] **  77.7 (18) 76.8 (17) 
Height [m] **  1.70 (0.09) 1.70 (0.09) 
Gender * Female 
Male 
37                              
28 
27                   
22 
CYP2C9 genotype * PM             
IM             
EM 
 2                     
15                   
31 
CYP2C19 genotype * PM             
IM             
EM 
 0                     
10                   
39 
CYP2D6 genotype * PM             
IM             
EM           
UM 
 1                     
18                   
29                   
1 
Alcohol consumption * No              
Yes 
56                             
9 
44                   
5 
Coffee consumption * No              
Yes 
11                             
54 
9                     
40 
Smoking * No              
Yes 
39                             
26 
25                   
24 
Mean blood pressure per patient    
[mm HG] ** 
Systolic      
Diastolic 
119 (12)                     
76 (8) 
119 (13)          
75 (8) 
Mean puls per patient [per minute] **  78 (8) 79 (6) 
Mean AST activity per patient [U/L] **  10.7 (3.8) 10 (2.9) 
Mean ALT activity per patient [U/L] **  16.0 (9.6) 13.8 (7.0) 
Mean γ-GT activity per patient [U/L] **  18.7 (38.4) 13.3 (8.9) 
Mean serum creatinine concentration 
per patient [mg/dL] ** 
 0.9 (0.1) 0.9 (0.2) 
*expressed as numbers of subjects within a specific category  
**mean (standard deviation )of all observations of a patient during investigation  
PM = poor metabolizers; IM = intermediate metabolizers EM = extensive metabolizers;  
UM = ultrarapid metabolizers 
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Figure 8. Boxplot of the relationship of mirtazapine daily dose to trough plasma 
concentrations (the median is indicated as black line, the quartiles are represented by 
shaded boxes and the range is expressed by error bars). 
 
Mean mirtazapine trough plasma concentrations of responders and nonresponders 
were analysed for a minimum threshold concentration by a receiver operating curve 
(Figure 9). The best distinction between true and false positive responders was found 
at a threshold concentration of 30 ng/mL. For confirmation, the proportions of 
responders and nonresponders were compared between groups at mean trough 
plasma concentrations below or above 30 ng/mL and the difference was found to be 
significant (χ2 = 6.017, df = 1, p = 0.014) (Table 16). Logistic regression analysis 
detected   a  small   but  significant  impact  of   the  individuals’   mean  trough  plasma  
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Figure 9. Receiver operating curve of response to mirtazapine treatment. The 
difference between sensitivity and 1-specificity is plotted against individuals’ mean 
trough plasma concentrations. 
 
concentration on the reponse to mirtazapine (χ2 = 4.371, df = 1, p = 0.031, Odds Ratio 
= 1.054 (95% confidence interval: 1.005 – 1.106)), whereas no influence was found 
with respect to gender, age, duration of treatment or the HAMD score at first 
observation.  
We tested the influence of mirtazapine trough plasma concentrations on the magnitude 
of the most frequently experienced side effects such as sedation, increased duration of 
sleep, weight gain and on the global assessment of the patient’s performance. 
Nonparametric correlation analysis of all observations yielded no significant correlation 
between trough plasma concentration and the degree of sedation, weight gain or 
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impairment of the patient’s performance. There was also no relationship between the 
number of additional sedative co-medication (benzodiazepines, antipsychotics, other 
sedative antidepressants, hypnotics or mood stabilisers) and the UKU item sedation or 
increased duration of sleep.  
When only observations during the first week of mirtazapine treatment were included in 
the analysis (n = 32) a weak negative correlation was detected between serum 
mirtazapine concentration and sedation (rS = - 0.321, p = 0.044) and increased duration 
of sleep  (rS =- 0.369, p = 0.019),  while a weak positive correlation  was seen  between 
increased duration of sleep and co-medication with antipsychotics (rS = 0.333, p = 
0.036) as well as with other sedative antidepressants (rS = 0.372, p = 0.018). We found 
no correlation between mirtazapine trough plasma concentration and weight gain.  
 
Table 16. χ2-Table for evaluation of a minimum threshold concentration for 
response to mirtazapine  
Total Nonresponder Responder Total 
Mean trough plasma concentration     
< 30 ng/mL 
17 5 22 
Mean trough plasma concentration     
> 30 ng/mL 
9 14 23 
Total 26 19 45 
 
 
To control the influence of co-medication on sedation, increased duration of sleep, 
weight gain or patient’s performance within this subgroup a logistic regression analysis 
was performed. The relationship between the occurence of increased duration of sleep 
and trough plasma concentration was confirmed (χ2 = 4.479, df = 1, p = 0.034, Odd’s 
Ratio = 0.925 (95% confidence interval: 0.861 – 0.994)); neither benzodiazepines nor 
antipsychotics, mood stabilisers or other antidepressants were relevant covariates on 
the absence or presence of the respective side effect.  
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4.2.3 Population pharmacokinetic analysis 
The following covariates were carried forward for population pharmacokinetic analysis 
of mirtazapine: height, weight, age, gender, males up to 48 years, smoking, alcohol 
and coffee consumption, the CYP2C9, CYP2C19 and CYP2D6 genotype as well as co-
medication with substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 
The number of patients that received inhibitors or inducers of CYP1A2, CYP2C9, 
CYP2C19, CYP2D6 or CYP3A4 were too small for further analysis. Serum creatinine, 
concentrations, liver enzyme activity, blood pressure and pulse were within a normal 
range and were therefore not further evaluated. Among patients taking mirtazapine, 
there was one patient with two defective alleles and another showing gene duplication 
of CYP2D6. As both patients did not present with conspicious plasma concentrations, 
the poor metabolizer was combined with the intermediate metabolizers and the 
ultrarapid metabolizer’s data were included within the group of extensive metabolizers. 
For the same reason, the data of two poor metabolizers of CYP2C9 were also grouped 
with the intermediate metabolizers. No poor metabolizer of CYP2C19 was detected 
within these patients. The distributions of functional alleles did not differ significantly 
from other groups referring to the CYP2D6 genotype (Griese et al. 1998) (χ2=2.664, 
df=3, p=0.446) or the CYP2C9 genotype (Taube et al. 2000) (χ2=2.282, df=2, p=0.319). 
Comparing the frequencies of intermediate and extensive CYP2C19 metabolizers 
reported previously (Xie et al. 1999) with the present data, no significant difference was 
found (χ2=0.551, df=1, p=0.458).  
The basic model was developed with a structural one-compartment model and first-
order absorption. As the data consisted of trough levels, the population mean was 
estimated only for clearance (ΘCL/F). The population mean of the absorption rate 
constant (k01) was fixed to 1.5 hr-1 as estimated from the nomograph of Franke and 
Ritschel  (1976)  by the  elimination rate constant and  the time to  reach  plasma peak  
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Figure 10. Precision of the HPLC method for quantification of mirtazapine plasma 
concentrations 
 
concentrations reported in the literature (Timmer et al. 2000). The volume of 
distribution (Vd/F) was fixed to 678 L as calculated according to Voortman and 
Paanakker (1995). Interindividual variability of clearance ηCL/F was assumed to obey 
normal distribution with a mean of zero. Pharmacokinetic parameters are usually log-
normally distributed, thus ηCL was included exponentially in the model:  
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Figure 11. Residual variability estimated by mixed-effects modeling of mirtazapine 
 
e FCLFCLCL η // ⋅=           Equation 18 
A multiplicative residual error model was applied: 
Cˆ
2
2 ⋅=σε            Equation 19 
The latter described best the amount and distribution of the residual error, that included 
the analytical assay error pattern (Frahnert et al. 2003) (Figure 10) as well as 
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deviations from the study protocol and model misspecifications. The estimated σ2 of 
0.08 resulted in a relative standard deviation of 28.3% (Figure 11). 
During the model building process, diagnostic plots and stepwise multiple linear 
regression analysis of ηCL detected the CYP2D6 genotype, smoking and co-medication 
with substrates of CYP3A4 as putative covariates. Then each covariate was included in 
the clearance mixed-effects specification in a stepwise forward manner to model 
interindividual variability (Table 17). 
As can be seen in table 17, the final model included the CYP2D6 genotype. This was 
the only covariate causing a significant drop in the objective function value and 
reducing the interindividual variability of clearance (CL/F) from 37.4% to 32.9%. The 
typical value for clearance (CL/F) in intermediate metabolizers was estimated to be 
26.4% lower than in extensive metabolizers.  
We found no other covariate that significantly increased the goodness-of-fit. The 
inclusion of smoking reduced the interindividual variability of clearance to 34.3% while 
estimating an 30% increase in the clearance (CL/F) of smokers, but the drop in the 
objective function value did not reach significance. Likewise, co-medication with 
substrates of CYP3A4 reduced the clearance (CL/F) by 20% but failed to cause a 
significant drop in the objective function value. 
Goodness-of-fit plots of the final model show observed trough plasma concentrations 
versus plasma concentrations estimated from population and individual 
pharmacokinetic parameters and weighted residuals (Figures 12 and 13). The 
histogram of individuals’ CL/F approximates log-normal distribution (Figure 14). A 
comparison of the distributions of individual’s ηCL/F showed that by inclusion of the 
covariate CYP2D6, the bimodal distribution of the basic model was transformed into a 
normal distribution in the final model (Figure 15).  
  
Table 17. Covariate model building for detection of factors influencing the clearance of mirtazapine 
Clearance specification Covariate 
specification
OFV ΘCL/F Θ1                    
Θ2 
ηCL/F σ2 
  Estimate SE Estimate SE Estimate SE Estimate SE 
ΘCL/F • eη * 1170.53 1170.99 96.82   0.101 0.030 0.080 0.008 
ΘCL/F eη • (1+ Θ1 • (CYP2D6-2)) ** IM=1, EM=2 1163.80 1319.20 172.89 0.264 0.101 0.081 0.028 0.079 0.008 
ΘCL/F • eη 1+ Θ1 • (CYP2D6-2)) •  (1+ Θ2 • 
smoking) 
IM=1, EM=2 
0=no, 1=yes 
1163.35 1175.92 136.98 0.231 
0.230 
0.080
0.132
0.073 0.020 0.079 0.011 
ΘCL/F • eη • (1+ Θ1 • (CYP2D6-2)) •  (1+ Θ2 • 
substrate CYP3A4) 
IM=1, EM=2 
0=no, 1=yes 
1162.24 1460.05 234.20 0.274      
-0.208 
0.010
0.113
0.069 0.015 0.079 0.005 
ΘCL/F • eη • (1+ Θ1*(CYP2D6-2)) • (1+ Θ2 • 
adult males) 
IM=1, EM=2 
0=no, 1=yes 
1166.09 1284.73 169.05 0.276      
-0.164 
0.086
0.141
0.079 0.026 0.079 0.008 
ΘCL/F • eη • (1+ Θ1 • smoking) 0=no, 1=yes 1168.08 1042.24 77.79 0.276 0.138 0.087 0.018 0.080 0.011 
ΘCL/F • eη • (1+ Θ1 • substrate CYP3A4) 0=no, 1=yes 1170.66 1282.93 157.00 -0.198 0.101 0.093 0.030 0.080 0.006 
ΘCL/F • eη • (1+ Θ1 • alcohol) 0=no, 1=yes 1171.22 1191.39 105.38 -0.081 0.028 0.101 0.031 0.078 0.008 
ΘCL/F • eη • (1+ Θ1 • substrate CYP2C19) 0=no, 1=yes 1172.30 1220.59 123.94 -0.177 0.104 0.098 0.032 0.080 0.007 
OFV: Minimum objective function value; ΘCL/F: Clearance scaled by bioavailability; Θ1, Θ2: Shift parameters for clearance; η: interindividual variability of 
clearance; σ2: Residual error; SE: Standard error; CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4: Cytochrome P450 isoenzymes 1A2, 2C9, 2C19, 2D6, 3A4   
* Basic model,  **Final model 
 
 
  
Table 17. Covariate model building for detection of factors influencing the clearance of mirtazapine (continued) 
Clearance specification Covariate OFV ΘCL/F Θ1 ηCL/F σ2 
specification  Estimate SE Estimate SE Estimate SE Estimate SE 
ΘCL/F • eη • (1+ Θ1 • gender)  ♂=0, ♀=1 1173.06 1244.92 134.64 -0.116 0.142 0.100 0.026 0.079 0.009 
ΘCL/F • eη • (1+ Θ1 • adult males)  0=no, 1=yes 1173.93 1145.43 115.74 0.109 0.159 0.102 0.032 0.080 0.008 
ΘCL/F • eη • (1+ Θ1 • substrate CYP1A2) 0=no, 1=yes 1174.07 1174.87 101.67 -0.051 0.169 0.102 0.031 0.080 0.008 
ΘCL/F • eη • (1+ Θ1 • substrate CYP2C9) 0=no, 1=yes 1174.36 1175.70 109.74 -0.028 0.158 0.104 0.032 0.080 0.008 
ΘCL/F • eη • (1+ Θ1 • substrate CYP2D6) 0=no, 1=yes 1174.44 1164.47 101.82 0.047 0.147 0.103 0.031 0.080 0.008 
ΘCL/F • eη • (1+ Θ1 • (CYP2C19-2)) IM=1, EM=2 1174.74 1172.37 110.21 0.006 0.143 0.104 0.030 0.080 0.008 
ΘCL/F • eη • (1+ Θ1 • coffee) 0=no, 1=yes 1176.53 1194.97 212.50 -0.022 0.169 0.104 0.035 0.080 0.009 
ΘCL/F • eη • (1+ Θ1 • (age-48)) age [y] 1181.29 1173.02 96.95 -0.003 0.004 0.103 0.032 0.080 0.008 
ΘCL/F • eη • (1+ Θ1 • *(height-170)) height [cm]    Failure to 
estimate 
    
ΘCL/F • eη • (1+ Θ1 • (CYP2C9)) IM=1, EM=2    Failure to 
estimate 
    
ΘCL/F • eη • (1+ Θ1 • (weight-78)) weight [kg]    Failure to 
estimate 
    
OFV: Minimum objective function value; ΘCL/F: Clearance scaled by bioavailability; Θ1, Θ2: Shift parameters for clearance; η: interindividual variability of 
clearance; σ2: Residual error; SE: Standard error; CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4: Cytochrome P450 isoenzymes 1A2, 2C9, 2C19, 2D6, 3A4   
* Basic model,  **Final model 
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Figure 12. Observed versus predicted mirtazapine trough plasma concentrations (A) predicted 
from the population clearance (B) predicted from the individual estimated clearances 
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Figure 13. Weighted residuals of mirtazapine trough plasma concentrations. (A) predicted from 
the population clearance (B) predicted from the estimated individual clearances 
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Figure 14. Distribution of individual predicted clearances (scaled by bioavailability) estimated by 
the final model 
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Figure 15. Comparison of the distribution of individual’s variability (ηCL/F) from the population 
mean of clearance (scaled by bioavailability) estimated by (A) the basic model and (B) the final 
model 
76                                                                                                                      Results 
4.3 Computer-assisted dose individualisation of lithium  
4.3.1 Patients characteristics 
The data for validation of the Bayesian curve fitting method consisted of 228 lithium 
serum concentrations from routine monitoring of 56 inpatients (Table 18).  
Patients’ charts were screened for covariates with possible influence on the 
pharmacokinetics of lithium and revealed co-medication with ACE inhibitors (n=6), 
calcium antagonists (n= 3), β receptorantagonists (n=8), thiazid diuretics (n=4), loop 
diuretics (n=1), diclofenac (n=1), and indomet acine (n=1).  
4.3.2 Validation of the method 
Trough plasma concentrations of each of the 56 patients were fitted with the help of the 
extended Abbottbase pharmacokinetic software®. The best fit was determined by 
stepwise  inclusion  of  each  covariate  that  was  noted  in  the  patients’  chart.   The  
 
Table 18. Patient characteristics for validation of the method for lithium dose 
individualisation 
Age [years] *  46.7 ± 13.7 (21 – 81) 
Height [cm] *  170 ± 8 (150–190) 
Weight [kg] *  74.6 ± 12.4 (55–119) 
Serum creatinine [mg/dL] *  0.95 ± 0.15 (0.7–1.3) 
Number of:    
Females   32 
Males  24 
Elderly  5 
Obesity   10 
Sweating or exsiccosis  2 
Co-medication with:  
Diuretics 5 
Antihypertensives 14 
NSAID 2 
*expressed as as mean ± standard deviation (range) 
 NSAID: Nonsteroidal antiinflammatory drugs 
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Table 19. Pharmacokinetic parameters estimated for 56 patients with the 
extended Abbottbase pharmacokinetic software® 
 Mean (Standard deviation) Range 
Sum of least squares  1.65 (1.45) 0.003-7.86 
Clearance [L/h] 1.11 (0.25) 0.46-1.77 
Central volume of distribution [L] 19.78 (8.26) 8.52-61.6 
Half-life [h] 13.2 (6.01) 6.29-36.6 
 
covariates specified in the software were also used to simulate other clinical situations 
where similar clinical effects were observed. A covariate was included in the patient’s 
model if it decreased the sum of least squares of the model fit. The estimated individual 
pharmacokinetic parameters obtained by the best fits of each patient are summarized 
in Table 19.  
The patients’ last observed plasma concentration was then carried forward to compare 
the predictive performance of the established method with three other methods 
described in the literature (Pepin et al. 1980, Jermain et al. 1991, Yukawa et al. 1993; 
Table 20). For that purpose, the individual pharmacokinetic parameters were estimated 
by Bayesian curve fitting, that included population pharmacokinetic parameters and all 
individual serum concentrations except for the last one. This concentration was then 
predicted by the individual pharmacokinetic parameters and compared to the observed 
concentration.  
 
Table 20. Predictive performance of the computer-assisted method for lithium 
dose individualisation compared to standard methods 
 Mean squared error Mean prediction error            
(95% Confidence interval) 
Present method  0.019 -0.023 (-0.014-0.053) 
Pepin et al. 1980 0.087 0.089 (0.013-0.160) 
Jermain et al. 1991 0.161 0.297 (0.075-0.246) 
Yukawa et al. 1993 0.042 -0.055 (-0.007-0.091) 
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Out of the 56 patients 21 were best fitted by inclusion of a covariate. However, the 
specified covariates did not always improve the curve fit. Best fits of the fourteen 
patients taking antihypertensives included this covariate in six individuals; four out of 
the five patients taking diuretics were better fitted with the covariate “diuretics”; one of 
the two patients taking nonsteroidal antiinflammatory drugs was better fitted including 
this covariate. The pharmacokinetics of one out of ten obese patients was better 
described by the covariate “obesity” and one of the five patients older than 70 years 
was better fitted with the help of the covariate “old age”. The inclusion of a linear 
relationship between creatinine clearance and lithium clearance led to a better fit for 
only one patient who had a serum creatinine concentration of 0.8 mg/dL.  
On the other hand, the pharmacokinetics of seven patients was better described  
Figure 16. Concentration-time-curve of a patient presenting with intensive sweating 
obtained by Bayesian curve fitting taking into account the observed serum 
concentrations (□): A without, B with modeling dehydratation at the first serum 
concentration measurement 
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including covariate specifications in comparable clinical situations: including the 
covariate “old age” led to a better fit for three patients who did not drink enough the 
change in clearance by intensive sweating or the combined effect of two 
antihypertensives was better reflected by the covariate “diuretics” (Figure 16). A 
change of diaphoretic co-medication was better explained by the inclusion of the 
covariate “nonsteroidal antiinflammatory drugs”. 
 
 
 
 
 

Discussion                                                                                                                    81 
 
5 Discussion 
In this thesis 136 patients were evaluated for an impact of CYP2C9, CYP2C19 and 
CYP2D6 polymorphisms on trough plasma concentrations, side effects and treatment 
response. These data mainly consisted of second generation antidepressants (93%) 
and demonstrated that changes in CYP2D6 and CYP2C19 enzyme activity and 
smoking significantly altered antidepressants’ trough plasma concentrations. The 
effects on plasma concentrations were of minor clinical relevance when the entire data 
were anaylsed but examination of poor and ultrarapid metabolizers indicated that 
trough plasma concentration measurement may be of relevance for substrates of 
CYP2D6 in cases of nonresponse or severe side effects.  
Providing a rationale for therapeutic drug monitoring of mirtazapine, a minimum 
threshold trough plasma concentration of 30 ng/mL may be used to optimise the dose 
of mirtazapine nonresponders. Dose adaption of mirtazapine may also be considered 
in patients with decreased CYP2D6 activity.  
The computer-assisted service for dose individualisation of lithium that was established 
in this thesis showed good precision and accuracy and was flexible with regard to 
dosing schedules, times of blood withdrawal and covariates influencing the 
pharmacokinetics of lithium.  
5.1 Impact of CYP2C9, CYP2C19 and CYP2D6 genotypes on treatment 
outcome 
The evaluation of the impact of CYP2C9, CYP2C19 and CYP2D6 on treatment 
outcome showed that (1) poor metabolizers of CYP2D6 and patients taking inhibitors of 
CYP2D6 had significantly higher mean dose-corrected trough plasma concentrations 
compared to the substance-specific median; (2) poor metabolizers of CYP2D6 were 
underrepresented (n=6) compared to the control group of healthy volunteers and (3) 
five of them experienced side effects that were judged relevant; (4) extensive 
metabolizers of CYP2C19 and smokers showed low mean dose-corrected plasma 
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concentrations compared to the substance-specific median; (5) mean trough plasma 
concentrations above or below the lower limit of a predefined minimum threshold 
concentration did not predict patients’ treatment outcome; (6) the HAMD score at first 
observation was associated with the HAMD-defined response at the end of the study 
period; (7) the CGI-defined lack of response was seen in patients that received a 
second antidepressant or benzodiazepines in the course of the study; (8) there was no 
general predictor for the occurrence of relevant side effects, but the administration of 
sedative co-medication was associated with the severity of serotonergic side effects. 
An overview of the current literature about the contribution of the cytochrome P450 
isoenzymes to the metabolism of the antidepressants evaluated in this thesis indicates 
that the three cytochrome P450 isoenzymes studied contribute to a different extent to 
the metabolism of the different drugs. Hydroxylation of amitriptyline, doxepin and 
clomipramine is predominantly catalysed by CYP2D6 while CYP2C19, CYP2D6, 
CYP2C9 and other isoenzymes are involved in demethylation. The impact of CYP2D6 
in the metabolism of amitriptyline and clomipramine is demonstrated in numerous 
studies whereas only one study showed significant differences in steady-state 
amitriptyline and clomipramine plasma concentrations between poor metabolizers and 
extensive metabolizers of CYP2C19. The relevance of CYP2C9 remains unclear and 
so far limited information is available of the influence of CYP isoenzymes for doxepin 
(Kirchheiner et al. 2001). Citalopram is metabolized to desmethylcitalopram by 
CYP2C19 and CYP3A4 and to didesmethycitalopram by CYP2D6. CYP2C19 is 
relevant for enantioselective demethylation of the active enatiomere S-citalopram 
(Hiemke and Härtter 2000). An association was found between citalopram 
demethylation and the mephenytoin metabolism, a probe drug for CYP2C19 as well as 
between the demethylation of desmethylcitalopram and the sparteine metabolism, a 
probe drug for CYP2D6 (Sindrup et al. 1993). Fluvoxamine metabolism is mediated by 
CYP1A2 and CYP2D6 (Chiba and Kobayashi 2000). A high and a low affinity metabolic 
pathway  were detected  for paroxetine,  the high affinity process  being saturable  and  
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Table 21. Contribution of CYP isoenzymes to the metabolism of the 
antidepressants – overview of current literature* 
 CYP2C9 CYP2C19 CYP2D6 
Amitriptyline + ++ ++ 
Citalopram - ++ + 
Clomipramine - ++ ++ 
Doxepin - ++ ++ 
Fluvoxamine - + + 
Mirtazapine - - + 
Paroxetine - - ++ 
Sertraline + + + 
Venlafaxine - - ++ 
++ involved, + little involved or - not involved in the metabolism of the antidepressant 
*Chiba and Kobayashi 2000; Dahl et al. 1997; Delbressine et al. 1998; Hiemke and Härtter 
2000, Kirchheiner et al. 2001; Sindrup et al. 1992; Sindrup et al. 1993 
 
mediated by CYP2D6 (Sindrup et al. 1992). Multiple isoenzymes are involved in the 
metabolism of sertraline in vivo, including CYP2D6, CYP3A4, CYP2C9 and CYP2C19, 
thus it is unlikely that changes in the metabolic capacitiy of a single isoenzyme 
significantly alters sertraline plasma concentrations (Kirchheiner et al. 2001). 
Mirtazapine is hydroxylated by CYP2D6 and CYP1A2 to 40% whereas 25% are N-
oxidated by CYP3A4 or excreted as glucuronides (Dahl et al. 1997, Delbressine et al. 
1998). O-demethylation by CYP2D6 is the main metabolic pathway of venlafaxine and 
was found to be associated with elevated plasma concentrations and arrythmia in poor 
metabolizers. CYP3A4, CYP2C9 and CYP2C19 are involved in N-demethylation of 
venlafaxine in vitro (Kirchheiner et al. 2001). Table 21 summarises the overview of 
current literature given in the preceeding paragraph. 
The patients evaluated in this thesis were mainly treated with second generation 
antidepressants. Unlike the tricyclic antidepressants the different cytochrome P450 
isoenzymes contribute to a varying extent to the metabolism of these drugs. Thus, the 
impact of CYP2D6 and CYP2C19 polymorphism on the treatment with new 
antidepressants can not easily be generalised. The most pronounced effect of CYP2D6 
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was expected for tricyclic antidepressants, venlafaxine and paroxetine whose main 
metabolic pathways are catalysed by this isoenzyme. Tricyclic antidepressants and 
citalopram were expected to be altered by CYP2C19. In addition, sertraline and 
amitriptyline might have been altered by CYP2C9. Taking into account the frequencies 
of antidepressants in the present study these data included 23% observations that 
should be markedly influenced by CYP2D6 activity, 45% of the data should also 
depend on CYP2C19 capacity and 15% may be altered by changes in the CYP2C9 
function. 
Evaluating these data, the impact of CYP2D6 activity was shown by elevated trough 
plasma concentrations when inhibitors of this isoenzyme were co-administered or when 
patients were poor metabolizers of CYP2D6. Although the analysis included only six 
poor metabolizers of CYP2D6, their trough plasma concentrations were significantly 
higher than the substance-specific median when analysing the entire data. This effect 
was even persistent when the poor metabolizer with the highest venlafaxine plasma 
concentration was excluded to check wether the significant result was only due to this 
outlier. Of note, trough plasma concentrations of venlafaxine were considerably 
increased in the poor metabolizer and decreased in the ultrarapid metabolizer of 
CYP2D6. Out of the six poor metabolizers of CYP2D6, five experienced relevant side 
effects at their first observation. These patients received doxepin, citalopram, sertraline 
and venlafaxine. Although until now only the association between high venlafaxine 
plasma concentrations and side effects was previously described, the incidence of 
relevant side effects in tended to be higher in poor metabolizers of CYP2D6 than in 
poor metabolizers of CYP2C19 or CYP2C9. 
In contrast to CYP2C9 or CYP2C19, the distribution of functional CYP2D6 alleles 
within our psychiatric patients differed significantly from a group of healthy Caucasian 
volunteers described by Griese and colleagues (1998). The number of poor 
metabolizers in psychiatric patients was smaller than expected. It is unlikely that this 
difference was caused by analytical errors because our method for CYP2D6 
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genotyping is well established and has proven to be reliable in another sample before 
(Lohmann et al. 2001). It has also been shown that the detection of the CYP2D6 alleles 
*1, *2, *3, *4, *5, *6 and the gene duplication is sufficient to accurately predict enzyme 
activity (Sachse et al. 1998). The poor metabolizer’s underrepresentation may be due 
to the fact that CYP2D6 poor metabolizers may be less willing to take antidepressant 
medication because of drug-related problems experienced in the past that were due to 
the drug’s elevated plasma concentrations. Indeed it has been demonstrated that the 
occurrence of side effects is associated with high plasma concentrations of venlafaxine 
and of old drugs such as tricyclic antidepressants (Preskorn 1993, Lessard et al. 1999). 
Another study evaluating tricyclic antidepressants already indicated a genotype-
dependent increase of side effects in patients treated with substrates of CYP2D6 
(Chou et al. 2000). Moreover, drug-related problems caused a higher rate of treatment 
discontinuation with greater risk of noncompliance (Montgomery and Kaser 1998).  
The impact of CYP2C19 was less pronounced than of CYP2D6. The analysis of our 
patients showed lower trough plasma concentrations in extensive metabolizers of 
CYP2C19 than in intermediate and poor metabolizers of this isoenzyme. Citalopram 
was the most frequently prescribed drug (37%) among the patients included in this 
analysis. It has been demonstrated by Sindrup and colleagues (1993) that the 
clearance of citalopram is twice as high in extensive metabolizers as in poor 
metabolizers of CYP2C19. However the results obtained with respect to CYP2C19 
were less clear than for CYP2D6. Our study included five poor metabolizers of 
CYP2C19 and two of them received amitriptyline or citalopram that were metabolized 
by this isoenzyme to a significant extent. The mean trough plasma concentration of the 
poor metabolizer receiving citalopram were 64% higher than the substance-specific 
median. The elevated amitriptyline trough plasma concentration of the other poor 
metabolizer of CYP2C19 may also be the result of multiple pharmacokinetic drug 
interactions: propranolol, a substrate of CYP2D6, and calcium channel blockers, that 
are substrates of CYP3A4, concur in the same metabolic pathways as amitriptyline; 
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sodium valproate may further raise amitriptyline plasma concentrations by enzyme 
inhibition (Bazire 2000). Another CYP2C19 poor metabolizer showed pronounced 
deviation from the sertraline-specific median, but trough plasma concentrations of 
sertraline are low compared to other antidepressants as they ranged from 20 to 50 
nl/mL, thus small changes in plasma concentrations resulted in high deviations from 
the population median. Only two CYP2C19 poor metabolizers experienced relevant 
side effects but they did not present with conspicious plasma concentrations.  
Neither the CYP2D6 genotype nor the CYP2C19 genotype were found to influence the 
occurrence of relevant side effects at treatment initialisation in our general logistic 
regression analysis. This may be due to the fact that 81% of the patients studied 
received second generation antidepressants with a lower risk of severe side effects at 
high plasma concentrations than the tricyclic antidepressants. These findings may 
indicate that the influence of genotypes on plasma concentrations of new 
antidepressants is of minor relevance in a naturalistic clinical setting were multiple 
factors influence plasma concentrations as well as treatment outcome. The severity of 
serotonergic side effects of patients taking SSRIs or venlafaxine were rated differently 
among the study centres. This centre effect may have been a further confounding 
factor. Analysing these patients receiving serotonergic medication, the only association 
was seen between the severity of side effects and sedative co-medication. This finding 
probably reflects symptomatic treatment with benzodiazepines or antipsychotics to 
control serotonergic side effects. This effect is also described in a Dutch study on add-
on medication of benzodiazepines in elderly patients (van Dijk et al. 2002). 
Plasma concentration monitoring is an accepted tool to avoid nonresponse and severe 
side effects of tricyclic antidepressants; therapeutic ranges of these substances are 
well established (American Psychiatric Association Task Force on the Use of 
Laboratory Tests in Psychiatry 1985). The advantage of therapeutic drug monitoring of 
new antidepressants still remains to be elucidated. If the activity of metabolising 
enzymes affects plasma concentration, it should also influence clinical outcome. 
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However, in our analysis, trough plasma concentrations above the currently 
recommended minimal threshold did not predict a better treatment response for these 
patients. Consequently, no relationship between genotype and treatment response was 
seen. There might be several reasons that, taken together, are responsible for the 
lacking impact of CYP2D6 and CYP2C19 polymorphisms on response: firstly, patients 
were mainly taking SSRIs or mirtazapine. Compared to TCAs or venlafaxine these 
drugs owe a small dosing range and a flat dose response-relationship. Thus, the 
frequency of subtherapeutic doses is probably low. Secondly, the impact of the 
isoeenzymes’ activity varies between the drugs but because of the small sample size, 
no subgroup analysis was carried out of patients taking antidepressants metabolized to 
a significant extent by CYP2D6 (amitriptyline, doxepin, venlafaxine, paroxetine) or 
CYP2C19 (amitriptyline, doxepin, citalopram). Thirdly, there were only four patients 
showing duplication of the CYP2D6 gene and at chance to show ultrarapid metabolism. 
Three of these patients were taking the CYP2D6 substrates amitriptyline, mirtazapine 
and venlafaxine but only venlafaxine’s dose-corrected plasma concentrations were 
36% lower than the substance-specific median. The fourth patient showed dose-
corrected sertraline plasma concentration 52% lower than the median. But as 
sertraline’s metabolism appears to be mediated by CYP3A4 it was unlikely to be 
affected by changes in the activity of CYP2D6 (Hiemke and Härtter 2000). Fourthly, 
within this natural clinical study design, a number of other factors such as additional 
psychotherapy or medication were likely to influence treatment outcome. When the 
response criteria were defined as 40% or more reduction in the HAMD score, the 
HAMD score at the first rating had a significant impact on treatment response. The 
finding that antidepressants were more effective in patients with severe depression is in 
accordance with Khan and colleagues (2002) who performed a meta analysis among 
45 clinical trials recorded in the database of the Food and Drug Administration. When 
response was defined according to the CGI, the physicians’ treatment strategy was 
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reflected: nonresponders were more likely to receive co-medication with a second 
antidepressant or a benzodiazepine. 
5.2 Therapeutic range and population pharmacokinetic analysis of 
mirtazapine 
The evaluation of a concentration-response relationship demonstrated marked 
variability of mirtazapine trough plasma concentrations, a small but significant relation 
of mirtazapine trough plasma concentration to treatment response and a trend of 
increased sedation and sleep at low mirtazapine trough plasma concentrations.  
Mirtazapine was prescribed in daily doses of 15, 30, 45 or 60 mg/day resulting in 
plasma concentrations ranging from 0-98 ng/mL, which is in close agreement with 
previous findings (Timmer et al. 1995). However, there was low correlation between 
dose and trough plasma concentration with marked variability within the dose levels. 
The reasons for this variability were studied later on by population pharmacokinetic 
analysis.  
The analysis of a minimum effective plasma concentration resulted in a threshold of 30 
ng/mL. The effect of trough plasma concentrations on the reduction of the HAMD score 
were small (Odd s Ratio = 1.056) but significant. Within this setting, treatment response 
might have been not only influenced by the mean trough mirtazapine plasma 
concentration but also by other factors. Therefore an additional logistic regression 
analysis was carried out that included age, gender, severity of illness, length of 
observation or Hamilton score at the first observation. However, these covariates did 
not significantly influence the reduction of the HAMD score from the first to the last 
observation. 
The response rate within our study was 42% which is lower than in pivotal clinical trials 
(Fawcett and Barkin 1998). There are different explanations for this finding. Firstly, the 
definition of response as 40% or more reduction in the HAMD-score might have been 
too rigid considering the fact that mirtazapine causes a mean drop in the HAMD-score 
of 25% in the first week and this time span was not taken into account in our study. 
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Secondly, no restriction was made in the study protocol that would have probable 
influence on the patient’s prognosis, such as severity of illness, number of depressive 
episodes in the past or co-morbidity. 
No naturalistic study was carried out so far that deteced a dose- or concentration-
response relationship for mirtazapine. One study that showed marked variability in the 
response rates of different investigators failed to show a difference between patients 
treated with daily doses of 5, 10, 20 or 40 mg (Organon, personal communication). 
There is only one double-blind study comparing the effectiveness of mirtazapine to 
imipramine in severely depressed patients. In this study, where dosing was adjusted for 
a target blood concentration range of 50-100 ng/mL for mirtazapine and 200-300 ng/mL 
for imipramine, impramine was more effective than mirtazapine (Bruijn et al. 1996). The 
mean daily dose of mirtazapine was 76 mg and thus markedly higher than in pivotal 
clinical trials. The patients in this study had experienced several depressive episodes in 
the past or were severly ill, thus it remains unclear if the reason for low performance of 
mirtazapine resides in treatment resistance or if high doses and thus high plasma 
concentrations might provide evidence for a curvilinear concentration-response 
relationship.  
However, in the present study extremly low or high plasma concentrations were 
underrepresented; this made it more difficult to detect minimum effective trough plasma 
concentrations or side effects related to high plasma concentrations. As physicians 
were free to choose initial doses and to adjust dosing schedules at about 4 weeks of 
treatment, nonresponders were more likely to receive high doses, thus no evaluation of 
maximum effective concentrations was carried out.  
Our analysis of the relationship between mirtazapine trough plasma concentrations and 
side effects focussed on side effects at low plasma concentrations and included a 
logistic regression analysis to control for possible covariates. The doses applied to the 
patients in our study were proved safe and effective in earlier clinical trials for 
marketing application (Fawcett and Barkin 1998), therefore the finding of good 
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tolerability was as expected. Mirtazapine side effects were assumed to be more 
prominent at initialisation of antidepressant medication than under chronic treatment. A 
relationship of trough plasma concentrations to side effects was therefore only found 
for the first week of treatment. The trend to increased sedative effect associated with 
increased duration of sleep at low plasma concentrations is in accordance with the 
findings of Kasper and colleagues who noted increased sedation at low doses of 
mirtazapine (Kasper et al. 1997). The reason for this may be mirtazapine’s higher 
affinity to histamine-H1 receptors than to serotonergic receptors; thus histamine-H1 
receptor blockade is more prominent at low plasma concentrations and is 
counterbalanced by serotonergic effects at higher plasma concentrations. Apart from 
sedation or increased duration of sleep, no significant relationship was detectable 
between trough plasma concentration, other UKU items (global assessment of the 
patient’s performance, sedation, weight gain), and co-medication.  
The population pharmacokinetic analysis of patients treated with mirtazapine 
demonstrated a significant difference in the mirtazapine clearance between extensive 
and intermediate metabolizers of CYP2D6.  
CYP2D6 and CYP1A2 catalyse the formation of 8-hydroxymirtazapine, the main 
metabolic pathway that contributes to 40% of mirtazapine’s metabolism in vivo 
(Delbressine et al. 1998). In vitro experiments have shown a 65% contribution of 
CYP2D6 to this pathway decreasing to 20% at a high mirtazapine concentration, while 
the contribution of CYP1A2 increases from 30% to 50% (Störmer et al. 2000). CYP2D6 
phenotyping with sparteine detected a five-fold lower clearance in intermediate 
metabolizers compared to extensive metabolizers, associated with a novel mutation in 
the flanking region of the CYP2D6 gene (Raimundo et al. 2000). Thus, our finding of a 
28% reduction in the mirtazapine clearance in intermediate metabolizers further 
supports the relevance of CYP2D6 in psychiatric clinical routine.  
No conspicious plasma concentration deviations were detected in the one poor 
metabolizer of these data neither has any report of high mirtazapine plasma 
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concentrations in poor metabolizers of CYP2D6 been published so far. One study 
comparing seven extensive metabolizers with seven poor metabolizers of debrisoquine 
found a 78% higher AUC of S-(+)-mirtazapine in poor metabolizers while the 
pharmacokinetics of the R-(-)-enantiomer remained unchanged; however, when 
analysing the racemate, no difference in mirtazapine pharmacokinetics was noted 
between poor and extensive metabolizers (Dahl et al. 1997). This finding is explained 
by enantioselective metabolism of mirtazapine: the S-(+)-enantiomer is predominantly 
hydroxylated via CYP2D6 and CYP1A2 and the R-(-)-enantiomer preferably undergoes 
N-oxidation and entero-hepatic recirculation as N+-glucuronide. The absence of a 
difference between poor and extensive metabolizers may be related to the decreasing 
relevance of CYP2D6 in favour of CYP1A2 with increasing mirtazapine exposure, 
suggesting that with low CYP2D6 activity other metabolic pathways become more 
relevant.  
One alternative metabolic pathway is 8-hydroxylation by CYP1A2. There are no 
polymorphisms with relevance to the metabolic function known for CYP1A2 but it is 
altered by several extrinsic factors. A case report has shown a three- to four-fold 
increase of mirtazapine serum concentrations after addition of fluvoxamine, a potent 
inhibitor of CYP1A2 (Anttila et al. 2001). As smoking is a known inducer of CYP1A2, it 
may also play a role in the clearance of mirtazapine. During model building a 30% 
increase of mirtazapine’s clearance was estimated reducing interindividual variability 
from 41.4% to 37.8%, although the model fit did not significantly improved compared to 
the basic model. This may be due to the residual variation of trough plasma 
concentrations within this naturalistic clinical study, that was estimated to be 27%, thus 
the analysis of a large sample size might have clarified the impact of smoking. 
The other alternative metabolic pathway is N-oxidation via CYP3A4. Mirtazapine 
plasma concentrations are found to decrease by 60% within the first weeks of co-
administration of carbamazepine, an inducer of CYP3A4 (Timmer et al. 2000). Only few 
of the patients evaluated in this thesis received carbamazepine, some of them just 
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initialising this co-medication, thus preventing to evaluate the long-term effect of this 
important covariate. However, a 20% lower clearance in patients co-medicated with 
substrates of CYP3A4 was noted together with a decrease in the interindividual 
variability of clearance. The effect was even more pronounced when this covariate was 
introduced in the final model but did not significantly improve the goodness-of-fit. 
Similar to smoking, this effect might be masked by the variability caused by the typical 
clinical setting. 
In our patients, neither influence of gender nor of age was detected on the clearance of 
mirtazapine. Previous findings reported a 50% higher AUC in adult males than in 
females or elderly (Timmer et al. 1996). The authors attributed this difference to altered 
clearance or volume of distribution between males and females or in the elderly. An 
effect on clearance was not supported by our clinical data. 
The study presented in this thesis was carried out under clinical conditions, thus the 
pharmacokinetics of mirtazapine was affected by multiple other factors such as 
reduced adherence to the dosing schedules or co-medication. Therefore the residual 
variability was considerable and model restrictions such as allowing no variability of the 
volume of distribution, bioavailability or absorption rate constant led to a further 
increase of this variability. In spite of these confounding factors, the effect of the 
CYP2D6 genotype was consistent during the entire process of model building 
suggesting this covariate to be pronounced even in this clinical setting. This effect may 
become relevant in the management of nonresponse associated with low plasma 
concentrations of extensive metabolizers. 
5.3 Dose individualisation of lithium 
Bayesian curve fitting with the extended Abbottbase pharmacokinetic software® 
allowed to generate individual serum concentration-time curves for every patient. The 
individual pharmacokinetic parameters estimated by this software were in accordance 
with the literature (Ritschel, 1992).  
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The accuracy to predict serum concentrations was good applying the extended 
Abbottbase pharmacokinetic software® or the method of Yukawa and colleagues 
(1993) as the prediction error was close to zero and the 95% confidence interval 
included 0. The method described by Pepin and colleagues (1980) tended to 
overestimate serum concentrations but the accuracy was still in line with those of 
commonly applied methods (Browne et al. 1988). This trend for overestimation was not 
present in other evaluations including 34 (Yukawa et al. 1993) or 20 patients (Browne 
et al. 1988) but in these evaluations the method of Pepin was found to be associated 
with high random variability. Validating our Bayesian method, dose individualisation 
according to Jermain and colleagues (1991) performed worse than other methods 
described in literature (Browne et al. 1988), the results of the present evaluation being 
in comparable to previous findings (Yukawa et al. 1993, Taright et al. 1994). Like the 
method of Yukawa et al. (1993), the method of Jermain et al. (1991) was established 
by nonlinear mixed-effects modeling but without evaluating the predictive performance 
as a final model check.  
The evaluations of Yukawa et al. (1993) and Taright et al. (1994) are the only studies 
published so far that used advanced population pharmacokinetic analysis to establish a 
dose individualisation method for lithium; the method of Taright et al. (1994) being 
based on nonparametric maximum likelihood estimation while the Yukawa method 
applied mixed effects modeling (Yukawa et al. 1993, Taright et al. 1994). Including the 
method established in this thesis that was based on the results of Taright and 
colleagues (1994), all validated methods that included the results of population 
pharmacokinetic analyses performed better than most of the standard methods (Table 
22). In contrast, the predictive performance was comparable to the test dose methods 
of Perry and colleagues (1986) or a nonlinear regression method (Williams et al. 1989) 
when Bayesian forecasting was based on standard pharmacokinetic data instead of 
advanced population pharmacokinetics (Table 22). 
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Table 22. Accuracy of methods to predict lithium serum concentrations – 
comparison with current literature 
 Our Bayesian 
method   
(n=60) * 
Browne     
et al. 1988 
(n=20) + 
Yukawa      
et al. 1993     
(n=34) * 
Williams      
et al. 1989 
(n=21) * 
Taright 
et al. 
1994 
(n=35) * 
Pepin 
method 
0.089      
(0.013-0.160) 
0.095        
(-0.14-0.27) 
0.01          
(-0.039-0.051)
  
Yukawa 
method 
-0.055        
(-0.007-0.091) 
 -0.02         
(-0.053-0.022)
 -0.04 
Jermain 
method 
0.297         
(0.075-0.246) 
 -0.02         
(-0.218-0.343)
 -0.44 
Other a 
priori 
methods 
 -0.155       
(-0.27-0.08) 
-0.02         
(-0.062-0.013)
  
Nomo-
graph  
 0.17         
(0.00-0.38) 
   
Nonlinear 
regression 
   -0.034        
(-0.125-0.053) 
 
Test dose 
of Perry 
 -0.06        
(-0.19-0.01) 
 -0.015        
(-0.075-0.035) 
 
Other 
Bayesian 
methods** 
-0.023        
(-0.014-0.053) 
  -0.042        
(-0.109-0.049) 
-0.01 
*expressed as mean prediction error (95% confidence interval)  
+expressed as median prediction error (95% confidence interval) 
** based on data obtained by standard pharmacokinetic analysis 
 
When comparing the 95% confidence interval of the prediction error of the four 
methods evaluated in this thesis, the prediction of our Bayesian method was the most 
precise followed by the method of Yukawa, Pepin and Jermain. The Bayesian method 
was the only one that also took individual serum concentrations or co-medication into 
account thus leading to better predictions. Both, our Bayesian method and the method 
according to Yukawa were among the most accurate when the 95% confidence 
intervals were compared to other findings (Table 22). The 95% confidence interval of 
accuracy of the Pepin method varies among the authors but Yukawa and colleagues 
(1994) also found the Jermain method to be less accurate. Table 22 compares the 
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accuracy of different techniques of dose individualisation evaluated in this thesis with 
the accuracies stated by Browne et al. (1988), Yukawa et al (1993), Williams et al. 
(1989) and Taright et al (1994).  
The inclusion of predefined covariates did not always improve the Bayesian curve fit of 
the extended Abbottbase pharmacokinetic software® but depended on the covariate 
and the clinical situation of the patients. The covariates “antihypertensives”, “diuretics” 
and “NSAID” described different degrees of reduction of the lithium clearance and 
performed well as far as no other covariate was present. In the presence of more than 
one factor influencing the pharmacokinetics of lithium, the appropriate covariate 
specification that best described their combined effect had to be chosen. For example 
when several drugs reducing the clearance of lithium were combined, as was the case 
for three patients, an additive effect was noted and either the covariate “diuretics” or a 
combination of the covariates “diuretics” and “antihypertensives” led to the best fit. The 
clinical situation of three other patients could be better understood by empiric inclusion 
of one of these covariates that mimiked for example extensive sweating or a change in 
diaphoretic medication. 
The covariate “old age” was useful to describe data of four patients that were thin and 
probably did not drink enough. Physiological changes in the elderly are commonly 
related to the body composition, with increasing body fat and decreasing total body 
water (Sproule et al. 2000). Thus the physiological state of a dehydrated patient may 
be comparable to that of the elderly. The covariate definition was based on a study that 
was carried out in the Seventies and the physiological status of old people at that time 
may have been worse than that of the five old patients evaluated in this thesis 
(Lehmann and Merten 1974). 
The inclusion of the covariate “obesity” did not explain pharmacokinetic variability of 
obese patients or any other clinical situation. One reason may be that the volume of 
distribution was calculated based on ideal body weight and therefore all patients were 
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automatically standardised by the Abbottbase pharmacokinetic software® with respect 
to weight and age. 
Including a linear relationship between lithium clearance and creatinine clearance 
calculated according to Cockcroft and Gault did not improve the model fit for most of 
the patients although all authors so far found renal function to be a crucial factor in the 
elimination of lithium. None of the patients included for validation of this method 
presented with a reduced glomerular filtration rate as serum creatinine concentrations 
ranged from 0.7 to 1.3 mg/dL. As the inclusion of this covariate should become 
especially relevant in renal impairment, its usefulness could not be adequately 
assessed in our patient group. 
Relying on the present data, the predefined covariates “diuretics”, “antihypertensives”, 
“NSAID” and “old age” may be of use in clinical routine and should be introduced after 
close examination of the patient’s state, especially when there are more factors 
possibly influencing lithium pharmacokinetics. Even other clinical situations may then 
be adequately described, as was shown for seven patients where the best fit was 
achieved by off-label use of one of these covariates. 
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These studies demonstrate that administering new generation antidepressants, the 
CYP2D6 genotype still significantly influences the plasma concentration. We observed 
a minor influence of the CYP2C19 genotype and no relevance of the CYP2C9 
genotype. The changes in plasma concentrations due to CYP2D6 polymorphism are 
most pronounced when venlafaxine is administered. The good tolerability of the new 
generation antidepressants may be the reason for the minor impact of genotypes on 
the occurrence of side effects. According to these results, genotyping by itself is no 
predictor for treatment response in a clinical setting, where the treatment outcome is 
influenced by multiple factors such as severity of illness, co-medication or additional 
treatment. Nevertheless, plasma concentration measurements may be useful to assess 
the patients’ actual metabolic capacity when treated with substrates of CYP2D6 and 
presenting with drug intolerance or nonresponse.  
This thesis also provides a basis for the therapeutic drug monitoring of mirtazapine. A 
positive correlation was confirmed between mirtazapine dose and trough plasma 
concentration but marked variability of plasma concentrations was seen. This 
variablility is partly determined by the CYP2D6 genotype. Other covariates that may 
also influence the pharmacokinetics of mirtazapine are co-medication affecting 
CYP3A4 activity or smoking. A minimum effective threshold concentration of 30 ng/mL 
for clinical routine is postulated providing a basis for therapeutic drug monitoring in 
nonresponders to mirtazapine treatment. Sedative effects such as increased duration 
of sleep may be more pronounced at low plasma concentrations whereas weight gain 
is not related to plasma concentration. To which extent high plasma concentrations 
may affect treatment outcome and side effects remains to be studied. 
In contrast to antidepressants, therapeutic drug monitoring is mandatory when lithium 
is administered. Several methods for dose individualisation of lithium are presented in 
the literature but they all necessitate prior knowledge of covariates and are based on 
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defined dosing schedules or times of blood withdrawal. It was demonstrated that dose 
individualisation of lithium is more flexible and thus more convenient for clinical routine 
when the Bayesian approach is used. The method presented in this thesis allows 
individual dose recommendations, independent of the dosing schedule or the time of 
blood withdrawal. Its predictive performance proved to be good when compared to 
standard a priori methods. Including covariates is not mandatory but may lead to a 
better understanding of the individual clinical situation. 
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Depression is the most frequent mental disorder occuring in 17% of the European 
population and its impact is assumed to grow in the next decades. Optimal treatment 
necessitates long-term administration of antidepressants in unipolar depressive 
disorder or mood stabilisers in bipolar disorder. Among mood stabilisers, lithium is the 
standard of care and therapeutic drug monitoring of lithium is mandatory to control wide 
interindividual variability in serum concentrations and to prevent severe intoxication. 
Several methods for dose individualisation of lithium are proposed in literature. Most of 
them require the adherence to defined dosing intervals, doses or serum concentration 
measurements and are therefore rarely applied in clinical routine. In this thesis a 
computer-assisted service for dose individualisation was established that applies 
population pharmacokinetic and individual data to predict and simulate serum 
concentrations by Bayesian curve fitting. This method is flexible with regard to dosing 
schedules and times of blood withdrawal and allows the inclusion of covariates. The 
predictive performance was compared to standard a priori methods for dose 
individualisation and showed good precision and accuracy. 
Antidepressants are first choice treatment of unipolar depression. They are equally 
effective but vary in their tolerability and side effect profile. Tricyclic and tetracyclic 
antidepressants possess a narrow therapeutic range, large interindividual variability 
and are therefore prone to the occurence of sub- or supratherapeutic plasma 
concentrations when standard doses are administered. Interindividual variability is due 
to drug interactions, renal or hepatic impairment, and genetic polymorphism of drug 
metabolising cytochrome P450 isoenzymes 2D6 or 2C19. For these drugs therapeutic 
drug monitoring is recommended to avoid nonresponse or toxic effects. Second 
generation antidepressants are also characterized by a large interindividual variability 
in plasma concentrations but most of them proved good tolerability, a flat dose-
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response relationship and less severe side effects. Therapeutic ranges are not well 
established and so far the usefulness of therapeutic drug monitoring is unclear.  
A multicentre naturalistic study was conducted to evaluate the relevance of therapeutic 
drug monitoring of amitriptyline, citalopram, clomipramine, desipramine, doxepin, 
fluvoxamine, imipramine, mirtazapine, nortriptyline, paroxetine, sertraline and 
venlafaxine. In this study inpatients’ severity of depression, side effects and trough 
plasma concentrations were recorded weekly. One hundred and thirty-six patients were 
recruited that also gave informed consent for an evaluation of the genetic factors 
underlying the response to antidepressive treatment. These data consisted to 93% of 
second generation antidepressants and were evaluated for an impact of CYP2C9, 
CYP2C19 and CYP2D6 polymorphisms on trough plasma concentrations, side effects 
and treatment response. It was demonstrated that CYP2D6 plays a significant role in 
the treatment with second generation antidepressants. The CYP2D6 genotype 
influenced dose-corrected trough plasma concentrations as they were significantly 
higher in the six poor metabolizers compared to the substance-specific median and five 
of them experienced side effects that were judged to be relevant. Plasma 
concentrations of patients taking inhibitors of CYP2D6 were higher than the substance-
specific median. Poor metabolizers of CYP2D6 were significantly underrepresented 
among psychiatric inpatients treated with psychotropic drugs compared to a control 
group of healthy volunteers, maybe because they were more susceptible to severe side 
effects and therefore refused to take antidepressants.  
The analysis also confirmed an impact of the CYP2C19 genotype or smoking on dose 
corrected trough plasma concentrations that were low in extensive metabolizers and 
smokers when compared to the substance-specific median. CYP2C9 polymorphism did 
not significantly influence patients’ trough plasma concentrations. 
The effects on trough plasma concentrations were of minor clinical relevance as mean 
plasma concentrations above or below the lower limit of currently accepted minimum 
threshold concentrations did not predict patients’ treatment outcome. Accordingly, no 
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association was seen between CYP2D6, CYP2C19 or CYP2C9 genotypes and 
response or the ocurrence of side effects at the beginning of antidepressive therapy. 
Some treatment strategies of the clinical routine turned out to be significant as 
nonresponders were more likely to receive a second antidepressant or 
benzodiazepines and the severity of serotonergic side effects was associated with 
sedative co-medication. Although the effect of genotypes was not distinct enough to be 
detectable for all antidepressants in the presence of multiple influencing factors of 
clinical routine, prominent plasma concentrations were seen for two patients that were 
poor or ultra rapid metabolizers of CYP2D6 and who received venlafaxine. Thus, 
plasma concentration measurements may be of relevance for substrates of CYP2D6 in 
cases of nonresponse or severe side effects. As the present investigation showed that 
the influence of genotypes on trough plasma concentration may be masked by multiple 
factors occuring in clinical routine, the determination of the actual enzyme activity by 
phenotyping or therapeutic drug monitoring may be of more clinical relevance than the 
determination of the patient’s genotype alone. 
Providing a basis for therapeutic drug monitoring of mirtazapine, patients that received 
this antidepressant were analysed separately for a concentration-effect relationship 
and to determine factors influencing its pharmacokinetics. Best distinction between 
responders and nonresponders to mirtazapine was achieved at a mean trough plasma 
concentration of 30 ng/mL. Sedation was more pronounced at low plasma 
concentrations, probably due to prominent histamine-H1 receptor blockade; for weight 
gain no association was shown. Population pharmacokinetic analysis was applied to 
detect factors influencing the pharmacokinetics of mirtazapine. The final model 
included the genotype of CYP2D6 as the only covariate significantly improving the 
model fit. In this analysis patients were divided in intermediate and extensive 
metabolizers, where one poor metabolizer entered the intermediate metabolizer group 
and one ultra rapid metabolizer joined the extensive metabolizers. Co-medication with 
substrates of CYP3A4 or smoking may be other influencing factors that require further 
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investigation. These findings indicate that therapeutic drug monitoring of mirtazapine 
may be beneficial in nonresponders. Dose adaption may be considered in patients with 
decreased CYP2D6 activity. 
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Appendix 1 
Hamilton Depression Rating Scale 
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Appendix 2 
UKU side effect rating scale 
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Appendix 3 
Clinical Global Impression Item 3 
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Appendix 4 
Request form for plasma concentration measurement 
(Including Clinical Global Impression Item 1 and 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
